Update date: February 1, 2024

Group No. 23: Palliative Care

ACETYLCYSTEINE

Clue	Description	Indications	Route of administration and dosage
	20% SOLUTION	Processes	Nasal nebulization.
		bronchopulmonary with	
	Each vial contains: Acetylcysteine	viscous hypersecretion and	Adults and children over 7 years old:
	400 mg.	mucostasis.	600 to 1000 mg/day, divided every 8 hours.
010.000.4326.00	Package with 5 vials with 2 mL (200 mg/mL).		Children from 2 to 7 years:
			300 mg/day, divided every 8 hours.
			Children up to 2 years:
			200 mg/day, divided every 12 hours.
		poisoning	Oral
		paracetamol.	
			Adults and children:
			Starting dose, 140 mg/kg body weight;
			then 70 mg/kg body weight, each
			4 hours, up to 18 doses or a 72-hour period.
		1	1

Sulphurous amino acid with fluidizing action on mucous and mucopurulent secretions in respiratory processes that cause hypersecretion and mucostasis.

Generalities

С Risk in Pregnancy Adverse effects Immediate hypersensitivity reactions, nausea, vomiting, headache, chills, fever, rhinorrhea, diarrhea, bronchospasm. Contraindications and Precautions Contraindications: Hypersensitivity to the drug, diabetes mellitus, gastroduodenal ulcer. Precautions: Asthma, use of tetracyclines. Interactions Antibiotics such as amphotericin, ampicillin sodium, erythromycin lactobionate and some tetracyclines are physically incompatible or can be inactivated by mixing with acetylcysteine.

ZOLEDRONIC ACID

	Clue	Description	Indications	Route of administration and dosage
		INJECTABLE SOLUTION	Regulator bone metabolism.	Intravenous infusion.
		Each vial with 5 mL contains:	Bone resorption inhibitor.	Adults:
		Zoledronic acid monohydrate equivalent to		4 mg for 15 minutes, every 3 or 4
		4.0 mg of zoledronic acid.		weeks.
			Treatment of	
	010.000.5468.00	Container with a vial.	hypercalcemia associated with neoplastic processes.	Administer diluted in intravenous solutions packaged in glass bottles.
,	N 2		Generalities	<u>.</u>

nd Multiple Myeloma.

It is a bisphosphonate, it inhibits bone reso	orption mediated by osteoclasts in neoplasias ar
Risk in P	regnancy c
	Adverse effects
Fever, nausea, vomiting, swelling at the in	fusion site, rash, pruritus, chest pain.
	Contraindications and Precautions
Contraindications: Hypersensitivity to the	drug, pregnancy, lactation, kidney or liver failure.
	Interactions
None of clinical importance.	

ALPRAZOLAM

Clue	Description	Indications	Route of administration and dosage
	TABLET	Anxiety.	Oral.
	Each tablet contains:	Panic disorders.	Adults:
	Alprazolam 2.0 mg		
040.000.2499.00	Container with 30 tablets.		0.5-4.0 mg per day.
	Each tablet contains:		Adults:
	Alprazolam 0.25mg		
040.000.2500.00	Container with 30 tablets.		Initial: 0.25 to 0.5 mg three times a day.
	Each tablet contains:		Maximum daily dose 4 mg in divided doses.
040.000.6298.00	Alprazolam 0.5mg Container with 30 tablets.		

Generalities

Benzodiazepine receptor agonist, which facilitates the inhibitory action of GABA in the central nervous system.

Risk in Pregnancy

Adverse effects

Drowsiness, lightheadedness, headache, hostility, hypotension, tachycardia, nausea, vomiting.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, acute glaucoma, psychosis and psychiatric disorders without anxiety. Precautions: Do not prescribe for everyday stress, it should not be administered for more than 4 months.

t presented for everyday stress, it should not be duffilliated for more than 4 months

Interactions

Alcohol and other central nervous system depressants increase the depressive state. Tricyclic antidepressants increase their plasma concentration.

AMITRIPTYLINE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Agitated depression,	Oral.
	Each tablet contains: hydrochloride	chronic reactive and with insomnia.	Adults:
	Amitriptyline 25mg		Initial: 25 mg every 6 to 12 hours and increase gradually.
040.000.3305.00	Package with 20 tablets.		Maintenance.150 mg in 24 hours.

Generalities

It inhibits the reuptake of serotonin and, to a lesser extent, norepinephrine in nerve endings.

Risk in Pregnancy

Adverse effects

d

Constipation, urinary retention, dry mouth, blurred vision, drowsiness, sedation, weakness, headache, orthostatic hypotension.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug or tricyclic antidepressants.

Precautions: In cardiovascular conditions, closed-angle glaucoma, active alcoholism, sedation and hyperthyroidism.

Interactions

Increases the hypertensive effect with adrenaline. Its effect decreases with barbiturates. With monoamine oxidase inhibitors, severe excitement, hyperthermia, and convulsions may occur.

APPREPITANT

Clue Description Indications Route of administration and dosage	e
---	---

	CAPSULE Each capsule contains: 125 mg of Aprepitant. Each capsule contains: 80 mg of	Nausea and vomiting associated with oncological therapy.	Oral. Adults: 125 mg during the first day. 80 mg during the second day and third day.
	Aprepitant.		oo nig during the second day and third day.
010.000.4442.00	Package with a 125 mg capsule and 2 capsules of 80 mg.		
		Generalities	1
Selective antagon	ist of substance P/neurokinin 1 recepto	ors.	
	Risk in Pregnancy	С	
	A	dverse effects	1
Fatigue, nausea,	constipation, diarrhea, anorexia, heada	che, vomiting, dizziness, del	nydration, abdominal pain, gastritis.
	Contraindic	cations and Precautions]
	: Hypersensitivity to the drug, terfenadirentiates the effect of medications that are		
		Interactions	1
With contraceptive	es and fluvastatin its effect decreases.		4

BECLOMETHASONE, DIPROPIONATE

Clue	Description	Indications	Route of administration and dosage
	AEROSOL SUSPENSION	Bronchial asthma.	Inhalation.
	Each inhalation contains:		Adults:
	Beclomethasone Dipropionate 50 µg.		Two to four inhalations, every 6 to 8 hours Maximum dosage 20 inhalations/day.
010.000.0477.00	Package with inhaler device for 200 doses.		waxiiidiii dosage 20 iiiilalatio15/day.
			Children from 6 to 12 years:
	AEROSOL SUSPENSION		One to two inhalations, every 6 or 8 hours.
			Maximum dosage 10 inhalations/day.
	Each inhalation contains:		
	Beclomethasone Dipropionate 250 µg.		
010.000.2508.00	Package with inhaler device for 200 doses.		

Generalities

It reduces bronchial inflammation, suppresses the immune response and influences the metabolism of proteins, fats and

Risk in Pregnancy	С
•	Adverse effects
Oropharyngeal candidiasis and irrita	tive symptoms.
	Contraindications and Precautions
Contraindications: Hypersensitivity	to the drug. Patients with hemostasis disorders, epistaxis and atrophic rhinitis.
	Interactions
None of clinical importance.	

BETAMETHASONE

carbohydrates.

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Serious inflammatory	Intramuscular, intravenous or intra-articular.
		processes.	
	Each vial or vial contains:		Adults:
		Immunosuppression.	0.5 to 9 mg/day.
	Betamethasone sodium phosphate		
	5.3 mg equivalent to 4 mg of	Allergic reactions.	Pregnant:
	betamethasone.		Intramuscular: 12 mg 36 to 48 hours before premature
L		į.	delivery.

010.000.2141.00 Container with a vial or a vial with 1 mL.	Prevention of neonatal respiratory distress syndrome.	Children: 625 µg at 3.75 mg/ m2 body surface area/ day, administered every 12 hours.
	Generalities	
It stimulates the transcription of mRNA, with a A2, inhibiting the synthesis of prostaglandins,		nzymes and indirectly blocks phospholipase
Risk in Pregn	ancy c	
	Adverse effects	
Gastric irritation, peptic ulcer, euphoria, inson osteoporosis, glaucoma, high blood pressure.		
	Contraindications and Precautions	
Contraindications: Hypersensitivity to the drugosteoporosis, high blood pressure, Cushing's		
	Interactions	
Its effect decreases with: phenobarbital, phenytoin, rifar	, ,	reases gastrointestinal irritation with non-steroidal anti-
inflammatory drugs and alcohol. Increases hypokalemia	produced by thiazides and furosemide.	

BIPERIDENE

Description	Indications	Route of administration and dosage
TABLET	Parkinsonism.	Oral.
Each tablet contains:	Motion sickness.	Adults:
Biperiden hydrochloride 2 mg.		1 mg every 12 hours. Increase the dose
Package with 50 tablets.		according to therapeutic response, up to a maximum of 4 mg every 8 hours. Dose
INJECTABLE SOLUTION		maximum 12 mg/day.
Each vial contains: Biperiden		Intramuscular or intravenous. Adults:
Container with 5 vials of 1 mL.		2 mg every 6 hours.
		Children:
		Intramuscular: 40 µg/kg body weight/ day, divided every 6 hours.
	TABLET Each tablet contains: Biperiden hydrochloride 2 mg. Package with 50 tablets. INJECTABLE SOLUTION Each vial contains: Biperiden lactate 5 mg.	TABLET Each tablet contains: Biperiden hydrochloride 2 mg. Package with 50 tablets. INJECTABLE SOLUTION Each vial contains: Biperiden lactate 5 mg.

Decreases central cholinergic activity, favoring the cholinergic-dopaminergic balance in the nervous system central.

Risk in Pregnancy c					
Adverse effects					
Constipation, dry mouth, urinary retention, blurred vision, restlessness, irritability and orthostatic hypotension.					
Contraindications and Precautions					
$Contraindications: Hypersensitivity\ to\ the\ drug.\ Glaucoma,\ epilepsy,\ cardiac\ arrhythmias,\ prostatic\ hypertrophy.$					
Interactions					
Muscarinic anticholinergic effects are increased with antipsychotics, antidepressants and atropine.					

BUDESONIDE

Clue	Description	Indications	Route of administration and dosage
	SUSPENSION FOR INHALATION	Allergic rhinitis.	Nasal.
	Each mL contains Budesonide 1,280mg		Adults:
010.000.4337.00	Container with spray bottle with 6 mL (120 doses of 64 µg each).		256 µg (4 doses) administered every 12 or 24 hours.

Generalities

С

Non-halogenated corticosteroid with anti-inflammatory capacity.

Risk in Pregnancy

Adverse effects

Mild pharyngeal irritation and cough, Candida infection, possibility of paradoxical bronchospasm.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: Pulmonary tuberculosis, fungal or viral infections in the respiratory tract.

Interactions

None of clinical importance.

BUPRENORPHINE

Clue	Description		Indications	Route of administration and dosage
040.000.2100.00 040.000.2100.01	SUBLINGUAL TABLET Each sublingual tablet contains: Buprenorphine hydrochloride equivalent to 0.2 mg of buprenorphi Package with 10 tablets. Package with 20 tablets. INJECTABLE SOLUTION Each vial or vial contains: Buprenorphine hydrochloride equivalent to 0.3 mg of buprenorphi Container with 6 vials or vials with 1	ine.	Pain of moderate to severe intensity secondary to: Acute myocardial infarction. Neoplasms. Terminal disease. Trauma.	Sublingual. Adults: 0.2 to 0.4 mg every 6 to 8 hours. Children: 3 to 6 mcg/kg body weight every 6 to 8 hours. Intramuscular or intravenous. Adults: 0.3 to 0.6 mg/day, divide doses every 6 hours. Maximum dose of 0.9 mg/day.
040.000.2098.00 040.000.2097.00	PATCH Each patch contains: Buprenorphine Package with 4 patches. PATCH Each patch contains: Buprenorphine Package with 4 patches.	20 mg. 30 mg.	Chronic pain of moderate to severe intensity secondary to: Neoplasms. Terminal disease. Trauma. Neuropathic pain.	Transdermal. Adults: The dose must be regulated and adjusted individually by evaluating the intensity of the pain. Initial dose of 17.5 to 35 µg/hour of buprenorphine Release rate 35 µg/hour of buprenorphine. Transdermal. Adults: The dose must be regulated and adjusted individually by evaluating the intensity of the pain. Release rate 52.5 µg/hour of buprenorphine.
040.000.6038.00	PATCH Each patch contains: Buprenorphine Package with 4 patches. Nominal release speed: 5µg/h (over a 7 day period). PATCH Each patch contains:	5mg	Chronic non-cancer pain of moderate intensity, when treatment with paracetamol and/or NSAIDs is ineffective or contraindicated.	Transdermal. Adults: The dose should be evaluated individually by evaluating the intensity of pain and the patient's analgesic response. Starting dose: one 5 mg patch (5 μ g/h) for 7 days.
040.000.6039.00	Buprenorphine Package with 4 patches. Rated release speed: 10µg/h (over a period of 7 days).	10mg		Do not apply more than two patches at a time regardless of the concentration, nor increase the dose at intervals les than 3 days.

Generalities	
Central action analgesic. It acts as a partial agonist of the µ-opioid receptor and antagonist of the ÿ-opioid receptor. Depending on the pain model and the route of administration, it is 25 to 100 times more powerful than morphine.	
Risk in Pregnancy x	
Adverse effects	
Sedation, dizziness, headache, miosis, nausea, sweating and respiratory depression.	
Contraindications and Precautions	
Contraindications: Hypersensitivity to the drug, intracranial hypertension, liver or kidney damage, depression of the central nervous system and prostatic hypertrophy. Precautions: In acute alcohol poisoning, convulsive syndrome, head trauma, shock and altered consciousness of origin to be determin	ned
Interactions	
With aleahal and triavalle antidepressants, their depressive effects increase. With MAO inhibitors, they but life at rick due to alterations	

With alcohol and tricyclic antidepressants, their depressive effects increase. With MAO inhibitors, they put life at risk due to alterations in the function of the central nervous system, respiratory and cardiovascular function. With other opiates, anesthetics, hypnotics, sedatives, antidepressants, neuroleptics and in general with medications that depress the central nervous system, the effects are enhanced. The effectiveness of buprenorphine can be enhanced (inhibitors) or weakened (inducers). of CYP 3A4.

CAPSAICIN

Clue	Description	Indications	Route of administration and dosage
	CREAM	Mild to moderate pain	Cutaneous.
		intensity in:	
	Each 100 grams contains:		Adults and people over 12 years old:
	Capsicum annuuna oleoresin extract equivalent	Rheumatoid arthritis.	
	to 0.035 g of capsaicin.	Osteoarthritis.	Manage according to the case and judgment
		Post-herpetic neuralgia.	of the specialist.
		Diabetic neuropathy.	
		Ghost member.	
010.000.4031.00	Container with 40 g.		

Generalities

Local action analgesic that exerts a selective desensitizing action, by suppressing the activity of type C sensory fibers and eliminating substance P from the nerve terminals.

Risk in Pregnancy b

Adverse effects

Erythema, burning at the application site that decreases in intensity with application in the first days of treatment.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, on wounded or irritated skin and mucous membranes.

Precautions: Apply to the affected area without rubbing. Do not apply simultaneously with another topical medication on the same area.

Interactions

None of clinical importance.

CARBAMAZEPINE

Clue	Description		Indications	Route of administration and dosage
	TABLET		Epilepsy.	Oral.
	Each tablet contains:		Generalized or partial	Adults:
	Carbamazepine 200 n	mg.	seizures.	
040.000.2608.00	Package with 20 tablets.			600 to 800 mg in 24 hours, divided every 8 to 12 hours.
				Children:

			10 to 30 mg/kg body weight/day, divided every 6 to 8 hours.	
	ORAL SUSPENSION			
	Each 5 mL contains:			
	Carbamazepine 100 mg.			
040.000.2609.00	Container with 120 mL and dispenser 5 mL.			
		Generalities		
It stabilizes the	neuronal membrane and limits seizur	e activity by inhibiting sodiur	m channels.	
	Risk in Pregnancy	С		
		Adverse effects		
Nausea, vomitir	ng, drowsiness, ataxia, vertigo, aplasti	c anemia, agranulocytosis.		
	Contrainc	lications and Precautions		
Contraindications: Hypersensitivity to the drug. Glaucoma, agranulocytosis, thrombocytopenia, aplastic anemia, kidney and liver failure.				
		Interactions		
Reduces the eff	ect of oral anticoagulants and hormor	nal contraceptives.		

CELECOXIB

Clue	Clue Description		Indications	Route of administration and dosage
	CAPSULE		Rheumatoid arthritis.	Oral.
	Each capsule contains:	100mg	Postoperative pain.	Adult:
		roomg	Osteoarthritis.	One or two capsules every 12 or 24 hours.
010.000.5505.00	Container with 20 capsules.			
	CAPSULE			
	Each capsule contains: Celecoxib	200mg		
010.000.5506.00	Container with 10 capsules.			

Generalities

Analgesic and non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits the enzyme cyclooxygense-2 (COX-2). It is almost completely absorbed orally, is 97% bound to plasma proteins, is extensively biotransformed in the liver, and inactive metabolites are eliminated in bile (27%) and urine (57%). Less than 3% is excreted in urine. Half-life of 11 hours.

Risk in Pregnancy C

Adverse effects

Abdominal pain, diarrhea, dyspepsia, flatulence, nausea, lower back pain, edema, headache, vertigo, rhinitis, pharyangitis and sinusitis. Melena, hypertension, anemia and allergic reactions occur in less than 2% of patients and in less than 0.1 % gastrointestinal perforation, hepatitis, arrhythmias and kidney damage.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug and non-steroidal anti-inflammatory drugs.

Precautions: Use under strict medical supervision and do not exceed the higher recommended doses, especially in patients with liver failure, heart and kidney failure and a history of acid-peptic disease.

Interactions

Increases the adverse effects of other NSAIDs and anticoagulants. Counteracts the effect of antihypertensives.

CITALOPRAM

Clue	Description	Indications	Route of administration and dosage

	TABLET	Depression.	Oral.		
	Each tablet contains: Hydrobromide		Adults:		
	of citalopram equivalent to 20 mg				
	of citalopram.		20 mg every 24 hours, the dose can be increased until the desired response is obtained.		
010.000.5487.01	Package with 28 tablets.				
	Γ	Generalities	¬		
Selective serotor	nin reuptake blocker, with no effect on		_		
	Risk in Pregnancy	С	_		
Headache, swear membranes.	ting, asthenia, weight loss, palpitation	Adverse effects ns, insomnia, decreased libio	do, nasal congestion, dry mucous		
Precautions: Risk	Hypersensitivity to the drug and in childred by the hildred by the	cy, lactation, mania, kidney t	failure and liver failure. In the second half increases; irritability, difficulty taking food		
		Interactions	٦		
	eutic activity. With triptans (eletriptan,	rse effects increase; ketocor			
V 0 1 1 3 7 7 7 7	\ A #				
LONAZEPA Clue I	1	Indications	Pouto of administration as a fine		
	Description SOLUTION	generalized epilepsy,	Route of administration and dosage Oral.		
	Each mL contains:	particularly the myoclonic, atonic and atonic-akinetic	Adults and children over 30 kg body weight		
	Clonazepam 2.5 mg.	varieties.	Adults and children over 30 kg body weight:		
040.000.2613.00	Container with 10 mL and integral dropper.		Initial dose: 0.5 mg every 8 hours, increase by 0.5 mg every three to seven days, until therapeutic effect is achieved. Maximum dose: 20 mg/day.		
			Children under 30 kg body weight: 0.01 to 0.03 mg/kg body weight/day, every 8 hours, then increase 0.25 to 0.5 mg every third day until the therapeutic effect is achieved. Maximum dose: 0.1 to 0.2 mg/kg body weight/day.		
		Generalities	7		
Benzodiazenine	that favors the inhibitory action of GA	Generalities BA. decreasing neuronal ac	니 tivitv.		
- on Eodiazohilie			y •		
	Risk in Pregnancy	С	_		
Phinard		Adverse effects	J		
Rhinorrhea, palpi muscular.	ıtatıoris, arowsiness, dizziness, ataxia	ı, nystagmus, exaggerated s	sedation, muscle relaxant effect, hypotonia		
Contraindications and Precautions Contraindications: Hypersensitivity to benzodiazepines, liver and kidney failure, glaucoma, lactation, psychosis, myasthenia gravis.					
Contraindications gravis.	Contraind		aucoma, lactation, psychosis, myasthenia		
	Contraind	s, liver and kidney failure, gl	aucoma, lactation, psychosis, myasthenia		
gravis.	Contraind	s, liver and kidney failure, gl Interactions			

LYSINE CLONIXINATE

333	Clue	Description		Indications	Route of administration and dosage
		INJECTABLE SOLUTION		Mild to moderate pain	Intramuscular or intravenous.
				intensity.	
		Each vial contains:			Adults:
		Clonixinate			
		Lysine	100 mg.		100 mg every 4 to 6 hours, maximum dose
			-		200 mg every 6 hours.
	010.000.4028.00	Container with 5 vials of 2 mL.			

Generalities

Cyclooxygenase inhibitor analgesic, blocking the synthesis of PGE and PGF2.

Risk in Pregnancy Adverse effects

Nausea, vomiting, drowsiness, dizziness and vertigo.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, breastfeeding, peptic ulcer, children under 12 years of age, high blood pressure and kidney or liver failure.

Interactions

With non-steroidal anti-inflammatory drugs, their gastrointestinal adverse effects may increase.

SODIUM CHLORAMPHENICOL-SULFACETAMIDE

Clue	Description	Indications	Route of administration and dosage
	OPHTHALMIC SUSPENSION	Infections produced	Ophthalmic.
		by susceptible bacteria.	
	Each 100 mL contains:		Adults and children:
	Left-handed chloramphenicol 0.5g		
	Sodium sulfacetamide 10g		One to two drops every 4 to 6 hours, according
			to each case.
010.000.2175.00	Container with integral dropper with 5 mL.		

Generalities

It inhibits protein synthesis by binding to the 50 S ribosomal subunit.

Risk in Pregnancy

Adverse effects

Local irritation. Hypersensitivity. Superinfections with prolonged use.

Contraindications and Precautions

Contraindications: Hypersensitivity to drugs, do not use in fungal or fungal eye conditions.

Newly born.

Precautions: Do not use for more than 7 days.

Interactions

None of clinical importance.

COMPOUND CHLORPHENAMINE

Clue	Description		Indications	Route of administration and dosage
	TABLET		symptomatic treatment	Oral.
			of the common cold.	
	Each tablet contains			Adults:
	Paracetamol	500 mg		One tablet every 8 hours.
	Caffeine	25 mg		
	Phenylephrine hydrochloride	5 mg		Children:
	Chlorphenamine maleate	4 mg		Its use is not recommended for children under 8 years of age.
0.000.2471.00	Package with 10 tablets.			

Generalities The combination of drugs exerts an antipyretic, antihistamine, vasoconstrictor and analgesic effect.

Risk in Pregnancy

		Adverse effects	
Drowsiness, agi			ry mucous membranes, headache and
	Control	adiantiana and Danas views	\neg
Contraindications: F	lypersensitivity to drugs, glaucoma, high bloo	ndications and Precautions d pressure, prostatic hypertrophy, gas	 stritis and duodenal ulcer.
		Interactions	
Adverse effects incr	ease with sedatives, hypnotics, anticoagulant	s, antidepressants, MAOIs and adren	ergic blockers.
0000000	U 00105		
SODIUM CH	LORIDE Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION AT 17.7%	Normalizer	Intravenous.
	1	severe sodium depletion.	1
	Each mL contains: Sodium chloride 0.177g	Shook due to homorrhage	Adults:
	0.177g	Shock due to hemorrhage and burns.	The volume should be adjusted according to the patient's
			age, body weight, cardiovascular or renal conditions, and
010.000.5386.00	Container with one hundred 10 mL vials.		the specialist's judgment.
		Generalities	\neg
Sodium is the m	ost important cation of the extracellula	ar fluid, in combination with chlo	orine it maintains osmotic pressure, acid-base
balance, and wa	ter balance. It contributes to nerve co	nduction, neuromuscular FUNC	CTION and glandular secretion.
	Risk in Pregnancy	то	
		Adverse effects	
	appropriate quantities it does not proc erosmolarity and hyperchloremic acid		ed in doses above what is required, edema,
	Contrai	ndications and Precautions	
	s: Hypernatremia or fluid retention.		
Precautions: Se	vere renal dysfunction, cardiopulmona		ension with or without edema.
None of clinical	importance	Interactions	_
None of clinical	importance.		
DEXAMETH	ASONE		
Clue	Description	Indications	Route of administration and dosage
	TABLET	Inflammatory processes	Oral.
	Each tablet contains	serious, such as:	Adults:
	Dexamethasone 0.5mg	Rheumatoid arthritis.	0.25 to 4 mg/day every 8 hours. The dose should be
	_		reduced gradually until the desired therapeutic effect is
010.000.3432.00	Package with 30 tablets.	Bursitis.	achieved.
		Ankylosing spondylitis.	Sustaining dose 0.5 to 1.5 mg/day, administered every 8 hours.
		Systemic lupus	Children:
		erythematosus.	0.2 to 0.3 mg/kg body weight day, dividing dose
I			every 8 hours.

Anti-inflammatory and anti-allergic glucocorticoid. Suppresses the immune response and stimulates the bone marrow.

Generalities

Risk in Pregnancy	С
	Adverse effects

, ,			eakness, hirsutism, adrenal insu	coma, peptic ulcer, increased appetite, ufficiency.
		Cantuain	disations and Durantinas	7
Contraina	ications: Hypersensitivity to		dications and Precautions	J
	•••	•	n, osteoporosis, diabetes mellitus	s, thromboembolism.
			Interactions]
			fect by biotransformation. Indom the development of hypokalemia	ethacin and aspirin increase the risk of a.
	ETHASONE			
Clu	Desc	ription	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	NC	Anemia and thrombocytopenia autoimmune.	Intravenous, intramuscular.
	Each vial or vial contain	ns:	Leukemia.	Adults:
	Dexamethasone sodium	n phosphate		4 to 20 mg/day, in higher doses divided
	equivalent to 8 mg. of d phosphate.	examethasone	Lymphoma.	every 6 to 8 hours. Maximum dose: 80 mg/ day.
010.000.424	11.00 Container with a vial or	viol with 2 ml	Intravascular coagulation syndrome.	Individualize dosage according to clinical
0.10.000.12	Container with a viai of	vidi witi z IIIL.	Cerebral edema.	response.
ı.	Petrol			! 7
	inflammation, stabilizing the row and influences protein, l	•	, , , , , , , , , , , , , , , , , , , ,	J s the immune response, stimulates the
	Risk	in Pregnancy	С	
			Adverse effects]
			a, peptic ulcer, euphoria, insomni injection sites, muscle weakness	ia, psychotic behavior, hypokalemia, s, withdrawal syndrome.
Contrainc	ications: Hypersensitivity to		dications and Precautions stemic infections, uncontrolled d] liabetes mellitus, glaucoma, gastritis.
Precautio	ns: Systemic arterial hyperte	nsion.		
			Interactions	1
\A/ith nhar	onharhital enhedrine and rife	mpin their elimina		n and aspirin increase the risk of

DEXMEDETOMIDINE

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Postoperative pain.	Continuous intravenous infusion.
	Each vial contains: Dexmedetomidine		Adults:
	hydrochloride 200 μg.		Initial: 1.0 ÿg/kg body weight for 10 minutes.
			Maintenance: 0.2 to 0.7 ÿg/kg body weight; the
			speed should be adjusted according to
010.000.0247.00 010.000.0247.01	Container with 1 vial.		the clinical response.
010.000.0247.01	Container with 5 vials. Container with 25 vials.		Administer diluted in intravenous solution packaged in glass bottles.

Generalities

It is an agonist of the ÿ2 adrenergic receptor of presynaptic and postsynaptic neurons of the spinal cord and locus ceruleus, which provides sedation and analgesia, without respiratory depression.

Risk in Pregnancy d

Adverse effects

Hypotension, hypertension, bradycardia, nausea and hypoxia.

	Ĭ	Contraindio	cations and Precautions	
	s: Hypersensitivity to the d	rug.		_
Precautions: Liv	er failure.		Interactions	٦
Ingrance the apost	hotic codative bypnotic and an	oid offects of sou	roflurane, isoflurane, propofol, alfei	
increases the anest	netic, sedative, hypnotic and opi	loid effects of sev	onurane, isonurane, proporoi, allei	itanii and midazolam.
DEXTROME	THORPHAN			
Clue	Description	ı	Indications	Route of administration and dosage
	SYRUP		Irritant cough.	Oral.
	Each 100 mL contains:			Adults and kids older than 12 years old:
	hydrobromide			
	dextromethorphan	200 mg.		30 to 45 mg every 6 or 8 hours.
010.000.2161.00	Container with 120 mL and disp	enser (10 mg/5		Children from 6 to 12 years:
	mL). SYRUP			40 to 20 mg ayan 6 at 8 hayra
	STRUF			10 to 20 mg every 6 or 8 hours.
	Each 100 mL contains:			
	hydrobromide dextromethorphan	300 mg.		
		300 mg.		
010.000.2431.00	Container with 60 mL and dispe	enser		
	(15 mg/5 mL).	9	1	_
			Generalities	
It suppresses the	e cough reflex by direct act	ion on the cou	igh center of the medulla obl	ongata.
Risk in Preg	nancy	С		
THOR III TO	jiidiloy			
	[А	dverse effects	
Drowsiness, dizz	ziness, nausea and dry mo	uth.		
	Í	Controlodio	actions and Drassutions	٦
Contraindication] e: Hyporeopeitivity to the d		cations and Precautions	_I astritis, peptic ulcer, emphysema, liver
	under 6 years old.	rug. Diabetes	meinus, bronchiai astiina, y	astitus, peptic dicer, empriysema, liver
	,		Interactions	7
With MAO inhibi	tors, antidepressants and t	ranquilizers.		
DIAZEPAM				
Clue	Description		Indications	Route of administration and dosage
	INJECTABLE SOLUTION		anxiety syndrome	Intramuscular or intravenous.
	Each vial contains:		widespread.	Adults:
	Diazepam	10 mg.	Convulsive syndrome.	5 to 10 mg a day.
040.000.0202.00	Container with 50 2 mL vials.		Epilepsy.	Maximum dose 20 mg.
040.000.0202.00	Container with 50 2 mL viais.		Muscle spasm.	Children weighing more than 10 kg body weight:
			Pre-anesthesia.	
				0.1 mg per kg of body weight. Single dose.
			Conorolitica	
			Generalities	J . , , , , , , , , , , , , , , , , , ,
sedation to hypn		ly on the centr	al nervous system, producin	g various degrees of depression, from
sedation to hypn	0313.			
	Risk in Pre	egnancy	d	
	<u>.</u>			
Despirator 6 9	una annualina auro-at contic.		dverse effects	J
	ire, cardiac arrest, urticaria, sis, dependence.	, nausea, vom	ıtıng, excitement, hallucinatio	ons, leukopenia, liver damage, phlebitis,
vendus unumbu	Jio, dependente.			
	[Contraindic	cations and Precautions	

Contraindications: Hypersensitivity to the drug, glaucoma, myasthenia gravis	, children under 10 kg of body weight, pregnancy, shock, use of other centra
nervous system depressants, the elderly and seriously ill, and kidney failure.	

1 4 4	
Interactions	

Enhances the effect of coumarins and antihypertensives. The association with disulfiram or tricyclic antidepressants enhances the effect of diazepam.

DULOXETINE

Clue	Description	Indications	Route of administration and dosage
	RELEASE CAPSULE	Depression.	Oral
	DELAYED		
		Pain from diabetic	Adults:
	Each delayed-release capsule contains:	peripheral neuropathy.	
			60 mg every 24 hours.
	Duloxetine hydrochloride equivalent to 60 mg. of		
	duloxetine.		
010.000.4485.00	Package with 14 delayed release capsules.		

Generalities

Duloxetine is a serotonin and norepinephrine reuptake inhibitor, and weakly inhibits dopamine uptake; without significant affinity for histaminergic, dopaminergic, cholinergic and adrenergic receptors.

Risk in Pregnancy C
Adverse effects

Constipation, diarrhea, dry mouth, nausea, vomiting, decreased appetite, weight loss, fatigue, dizziness, headache, drowsiness, tremor, increased sweating, hot flashes, blurred vision, anorgasmia, insomnia, decreased libido, delayed sleep ejaculation, ejaculation disorder, erectile dysfunction.

Contraindications and Precautions

Contraindications: hypersensitivity to the drug. Duloxetine should not be used in combination with a monoamine oxidase inhibitor, or within 14 days of stopping treatment with an MAOI.

Precautions. Activation of mania/hypomania, seizures, mydriasis, renal or hepatic failure, effects on the ability to drive and operate machinery, suicide.

Interactions

Administration with CYP1A2 inhibitors, drugs metabolized by CYP2D6, and CYP2D6 inhibitors should be done with caution.

ERYTHROPOIETIN

		Route of administration and dosage
JECTABLE SOLUTION	Insufficiency anemia	Intravenous or subcutaneous.
	chronic kidney.	
ach vial with lyophilisate or solution contains:		Adults:
		Initial: 50 to 100 IU/kg body weight three times a week.
combinant human erythropoietin or		
		Support: 25 IU/kg body weight three times a week.
ythropoietin alfa or Erythropoietin beta 4000 IU.		
ackage with 6 vials with or without diluent.		
ackage with 1 prefilled syrings		
ackage with 1 premied syninge.		
ackage with 6 prefilled syringes.		
y	ombinant human erythropoietin or thropoietin alfa or Erythropoietin beta 4000 IU. ckage with 6 vials with or without diluent. ckage with 1 prefilled syringe.	ch vial with lyophilisate or solution contains: chapter of thropoletin alfa or Erythropoletin beta 4000 IU. ckage with 6 vials with or without diluent. ckage with 1 prefilled syringe.

(Seneralities

Hormone that acts on the bone marrow, promoting the formation of erythrocytes.

Risk in Pregnancy

Adverse effects

High blood pressure, headache, seizures.

Contraindications and Precautions

Contraindications:	Hypersensitivity to the drug			
	with caution in patients with		ressure, epilepsy and seiz	ure syndrome.
Name of all to all to			Interactions	
None of clinical im	portance.			
SCITALOPE	RAM			
Clue	Description TABLET		Indications Depression.	Route of administration and dosage Oral.
	Each tablet contains:		Depression.	Adults:
	Escitalopram oxalate			Addito.
	equivalent to escitalopram.	10mg		10 mg every 24 hours, then the dose can be increased to a maximum of 20 mg.
010.000.4480.01	Package with 28 tablets.			
				_ <u></u>
Salaatiya saratanir	reuptake blocker, with no		Generalities	
Selective serotoriii	————————	enect on othe	er neurotransmitters.	
Risk in Pregn	ancy	С		
		A	dverse effects	
Headache, nausea	a, vomiting, diarrhea, dry mo	outh, drowsin	ess, insomnia, dizziness,	oruritus, angioedema, sweating.
	Г	Contraindic	ations and Precautions	
	hypersensitivity to the drug			
•	•			In the second half of pregnancy, the risk of Ity taking food and respiratory difficulty in RNs.
r orolotont r uniform	ary risportantial or the rect		iorodooo, irridoiity, diiriod	ity taking 1000 and 100phatory announcy in 11110.
	Г		Interactions	\neg
With MAO inhibitor	ــــ rs, tramadol, alterations in s	erum concer	ntration have been observe	ed when administered with omeprazole,
cimetidine, desipra Serotonin Syndron	•	triptans (eleti	riptan, rizatriptan, sumatrip	etan and zolmitriptan) severe, life-threatening
Serotoriin Syndron	ne occurs.			
THOFENAM				
Clue	Description INJECTABLE SOLUTION		Indications Rheumatoid arthritis	Route of administration and dosage Intramuscular.
	INSECTABLE GOLOTION		Ankylosing spondylitis	
	Each vial contains: etofenamate	1g.	Osteoarthrosis and spondyloarthrosis.	Adults:
010.000.4036.00		.9.	Painful shoulder.	One vial of 1 g every 24 hours, up to a maximum of three.
010.000.4036.00	Container with a 2 mL vial.		Lumbago. Sciatica.	or unee.
			Stiff neck. Tenosynovitis.	
			Bursitis. Acute attack of gout.	
			Acute attack or gout.	<u></u>
Daring distance (last)			Generalities	
Derived from fluter	namic acid that inhibits the s	syntnesis of p	prostagiandins, leukotriene	s, bradykinin, histamine and complement.
			С	
	Risk in Preg	nancy		
			dverse effects	
Hypersensitivity re	actions, headache, vertigo,	nausea, von	niting, dizziness, fatigue, d	ysuria and epigastric pain.
		Contraindic	ations and Precautions	
	• • • • •	, alterations	in coagulation and hemato	poiesis, gastric or duodenal ulcer, kidney, liver
	egnancy and lactation. nistration is not recommended in	children under	14 years of age.	

With corticosteroids or other anti-inflammatories it can cause acid-peptic disease. It may reduce the action of furosemide, thiazides and beta-blocking antihypertensives. It can increase the plasma level of digoxin, phenytoin, methotrexate, lithium or oral hypoglycemic agents, its excretion decreases with probenecid and sulfinpyrazone.

PHENYTOIN

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Epilepsy.	Intravenous.
	Each vial contains: Phenytoin sodium 250 mg	Generalized and partial	Adults:
	Phenytoin sodium 250 mg.	crises.	100 mg every 8 hours. Increase 50 mg/day/ week, until therapeutic response is obtained.
010.000.2624.00	Package with one vial (250 mg/5 mL).	Neuropathic pain.	
			Intravenous: 5 mg/kg without exceeding 50 mg/ minute.
			minute.
			Administer diluted in intravenous solutions
			packaged in glass bottles.
L			

Generalities

It stabilizes the neuronal membrane and limits seizure activity by inhibiting sodium channels.

Risk in Pregnancy d

Adverse effects

Nausea, vomiting, nystagmus, megaloblastic anemia, jaundice, ataxia, gingival hypertrophy, hirsutism, ventricular fibrillation, hepatitis.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Liver, heart or kidney failure; aplastic anemia, lupus erythematosus, lymphomas.

Interactions

With tricyclic antidepressants its toxicity increases. Chloramphenicol, coumarins, and isoniazid increase their adverse effects. They reduce the effect of hormonal contraceptives, steroids, diazoxide, dopamine, furosemide, levodopa and quinidine.

FENTANYL

Clue	Description	Indications	Route of administration and dosage
	PATCH	Chronic pain.	Transdermal.
	Each patch contains: Fentanyl	Pain syndrome.	Adults:
	4.2 mg.		4.2 mg every 72 hours. Maximum dose 10 mg.
		Intractable pain requiring opioid	
040.000.4027.00	Package with 5 patches.	analgesia.	
			Requires a narcotic prescription.

Generalities

Opioid agonist that acts mainly on μ and \ddot{y} receptors. It produces a state of deep analgesia and unconsciousness. It is 50 to 100 times more powerful than morphine.

Risk in Pregnancy c

Adverse effects

Respiratory depression, sedation, nausea, vomiting, muscle rigidity, euphoria, bronchoconstriction, orthostatic arterial hypotension, constipation, headache, confusion, hallucinations, miosis, bradycardia, seizures and pruritus.

Contraindications and Precautions

Contraindications: Hypersensitivity to fentanyl and opioids, treatment with monoamine oxidase inhibitors, head trauma, intracranial hypertension and respiratory dysfunction, cardiac arrhythmias, psychosis and hypothyroidism.

Precautions: Children under 12 years of age.

Interactions	

Associated with benzodiazepines it produces respiratory depression. Monoamine oxidase inhibitors potentiate the effects of fentanyl. Increase its concentration with ritonavir.

FLUOXETINE

Clue	Description	Indications	Route of administration and dosage
	CAPSULE OR TABLET	Depression.	Oral.
	Each capsule or tablet contains: Fluoxetine hydrochloride equivalent to 20		Adults:
	mg of fluoxetine.		Initial: 20 mg in the morning, with progressive increase according to the response.
010.000.4483.00	Package with 14 capsules or tablets.		
010.000.4483.01	Package with 28 capsules or tablets.		Maximum dose 80 mg/day.

Generalities

It inhibits the reuptake of serotonin by neurons in the central nervous system.

Risk in Pregnancy b

Adverse effects

Nervousness, anxiety, insomnia, bradycardia, arrhythmias, nasal congestion, visual disorders, respiratory discomfort, sexual dysfunction, urinary retention, hypersensitivity reactions.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: In the elderly, liver and kidney failure and breastfeeding. History of epilepsy and seizure syndrome, administer lower doses. In the second half of pregnancy, the risk of Persistent Pulmonary Hypertension of the Newborn (PN) increases; irritability, difficulty taking food and respiratory difficulty in RNs.

Interactions

With warfarin and digitoxin, its adverse effects are enhanced. Increases the effect of central nervous system depressants. With triptans (eletriptan, rizatriptan, sumatriptan and zolmitriptan) severe, life-threatening Serotonin Syndrome occurs.

FUROSEMIDE

Clue	Description		Indications	Route of administration and dosage
	ORAL SOLUTION		Edema associated with:	Oral.
	Each mL contains:	40	Renal insufficiency.	Adults:
010.000.2157.00		10 mg.	Heart failure.	20 to 80 mg every 24 hours.
010.000.2137.00	Container with a 60 mL dropper bo	ttle.	Liver failure.	Children:
	TABLET		Acute pulmonary edema.	2 mg/kg body weight/day every 8 hours.
	Each tablet contains:		Acute pullionary edema.	2 mg/kg body weight/day every 6 hours.
	Furosemide	40 mg.		Maximum dose 6 mg/kg body weight/ day.
010.000.2307.00	Package with 20 tablets.			
	INJECTABLE SOLUTION			Intravenous or intramuscular.
	Each vial contains:			Adults:
	Furosemide	20 mg.		100 to 200 mg.
010.000.2308.00	Container with 5 vials of 2 mL.			Children: Initial: 1 mg/kg body weight, increase the dose by 1 mg every 2 hours until the therapeutic effect is found. Maximum dose: 6 mg/kg/day.

Generalities

	Diek in Program	ncy X	
	Risk in Pregnar	<u>ıcy</u> ^	
		Adverse effects	
	che, hypokalemia, metabolic alki nypomagnesemia.	alosis, arterial hypotension, trans	sient deafness, hyperuricemia, hyponatremia,
	Со	ntraindications and Precautions	
	ns: Hypersensitivity to the drug, ր /droelectrolyte imbalance.	pregnancy in the first trimester ar	nd liver failure.
		Interactions	
With aminoglyce	osides or cephalosporins, nephro	otoxicity increases. Indomethacir	n inhibits the diuretic effect.
GABAPENT	īN		
Clue	Description	Indications	Route of administration and dosage
	CAPSULE	Epilepsy.	Oral.
	Each capsule contains:	Convulsive syndrome with	Adults and kids older than 12 years old:
	Gabapentin 300 n	ng. generalized or partial seizures.	300 to 600 mg every 8 hours.
010.000.4359.00	Container with 15 capsules.	Neuropathic pain.	
		Generalities	<u>.</u>
Analog of gamma-a	minobutyric acid (GABA) that increases	the promoted release of GABA through a	an unknown process.
0 0			·
Risk in Pre	gnancy	С	
,		A di # + -	
		Adverse effects	
Ataxia, nystagm	ius, amnesia, depression, irritabi	ility, drowsiness and leukopenia.	
	Co	ontraindications and Precautions	
		THE THE TENED TO T	<u> </u>
Contraindication	ns: Hypersensitivity to the drug, a	assess the need for its use during	g pregnancy and lactation.
		Interactions	
It may increase decrease their b		tem depressants, such as alcoho	ol. Antacids with aluminum or magnesium
0000=			
	T =	In directions	Davis of administration and decays
		Indications	
GLUCOSE Clue	Description 50% INJECTABLE SOLUTION	Caloric intake.	Route of administration and dosage Intravenous.
			Intravenous.
	50% INJECTABLE SOLUTION	Caloric intake. Hypertonic	Intravenous. Adults and children:
GLUCOSE Clue	50% INJECTABLE SOLUTION Each 100 mL contains:	Caloric intake. Hypertonic dehydration. 50.00 Water deficiency.	Intravenous.
	50% INJECTABLE SOLUTION Each 100 mL contains: Anhydrous glucose or glucose 50 g Glucose monohydrate equivalent to	Caloric intake. Hypertonic dehydration.	Intravenous. Adults and children: According to the patient's daily energy requirements, body weight, age, cardiovascular and
Clue	50% INJECTABLE SOLUTION Each 100 mL contains: Anhydrous glucose or glucose 50 g Glucose monohydrate equivalent to g of glucose.	Caloric intake. Hypertonic dehydration. 50.00 Water deficiency. Energy supplement. Hypoglycemia induced by	Intravenous. Adults and children: According to the patient's daily energy requirements, body weight, age, cardiovascular and
Clue	50% INJECTABLE SOLUTION Each 100 mL contains: Anhydrous glucose or glucose 50 g Glucose monohydrate equivalent to g of glucose. Container with 50 mL.	Caloric intake. Hypertonic dehydration. 9 50.0 Water deficiency. Energy supplement.	Intravenous. Adults and children: According to the patient's daily energy requirements, body weight, age, cardiovascular and
Clue	50% INJECTABLE SOLUTION Each 100 mL contains: Anhydrous glucose or glucose 50 g Glucose monohydrate equivalent to g of glucose. Container with 50 mL.	Caloric intake. Hypertonic dehydration. 9 50.0 Water deficiency. Energy supplement. Hypoglycemia induced by insulin or oral	Intravenous. Adults and children: According to the patient's daily energy requirements, body weight, age, cardiovascular and
Clue 010.000.3607.00 Glucose is the	50% INJECTABLE SOLUTION Each 100 mL contains: Anhydrous glucose or glucose 50 g Glucose monohydrate equivalent to g of glucose. Container with 50 mL. Contains: Glucose 25.0 g	Caloric intake. Hypertonic dehydration. 50 50.0 Water deficiency. Energy supplement. Hypoglycemia induced by insulin or oral hypoglycemic agents.	Intravenous. Adults and children: According to the patient's daily energy requirements, body weight, age, cardiovascular and renal condition and degree of dehydration.
Clue 010.000.3607.00 Glucose is the	50% INJECTABLE SOLUTION Each 100 mL contains: Anhydrous glucose or glucose 50 g Glucose monohydrate equivalent to g of glucose. Container with 50 mL. Contains: Glucose 25.0 g	Caloric intake. Hypertonic dehydration. Discoil 1950.0 Water deficiency. Energy supplement. Hypoglycemia induced by insulin or oral hypoglycemic agents. Generalities organisms. Injectable solutions with the solutions with the solutions with the solutions with the solution of the	Intravenous. Adults and children: According to the patient's daily energy requirements, body weight, age, cardiovascular and renal condition and degree of dehydration.
Clue 010.000.3607.00 Glucose is the	50% INJECTABLE SOLUTION Each 100 mL contains: Anhydrous glucose or glucose 50 g Glucose monohydrate equivalent to g of glucose. Container with 50 mL. Contains: Glucose 25.0 g main source of energy in living of ce of calories; They cover water in	Caloric intake. Hypertonic dehydration. Discoil 1950.0 Water deficiency. Energy supplement. Hypoglycemia induced by insulin or oral hypoglycemic agents. Generalities organisms. Injectable solutions with the solutions with the solutions with the solutions with the solution of the	Intravenous. Adults and children: According to the patient's daily energy requirements, body weight, age, cardiovascular and renal condition and degree of dehydration.

Contraindications and Precautions	

Contraindications: 50% solution in osmotic diuresis, intracaneal or intraspinal hemorrhage, delirium tremens. Precautions: restrict its use in edema with or without hyponatremia, heart or kidney failure, hyperglycemia, diabetic coma.

44		
	Interactions	

Hyperglycemia is favored with medications such as corticosteroids, thiazide diuretics, and furosemide.

HALOPERIDOL

Clue	Description	Indications	Route of administration and dosage
	ORAL SOLUTION	Psychosis.	Oral.
	Each mL contains: Haloperidol 2m	Neuroleptic.	Adults 0.5 to 5 mg every 8 to 12 hours.
040.000.4477.00 040.000.4477.01	Container with integral dropper with 15 mL.	Psychomotor arousal.	
	Container with integral dropper with 30 mL.		
	TABLET		Oral.
	Each tablet contains: Haloperidol 5m	a	Adults:
040.000.3251.00	Package with 20 tablets.	9	5 to 30 mg in 24 hours. One dose per day or divide doses every 8 to 12 hours.
	INJECTABLE SOLUTION		Intramuscular.
	Each vial contains: Haloperidol 5 m	g.	Adults:
040.000.3253.00	Container with 6 vials (5 mg/ mL).		2 to 5 mg every 4 to 8 hours.
	INJECTABLE SOLUTION		Intramuscular.
	Each vial contains: Haloperidol decanoate		Adults:
	equivalent to 50 m haloperidol.	ng	50 to 100 mg every 4 weeks.
040.000.4481.00 040.000.4481.01	Container with 1 vial with 1 mL. Container with 5 vials with 1 mL.		

Generalities

It blocks postsynaptic dopamine receptors in the brain.

Risk in Pregnancy C

Adverse effects

Dry mucous membranes, constipation, urinary retention orthostatic hypotension, extrapyramidal symptoms, dyskinesia

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. The injectable solution should not be administered intravenously because it causes serious cardiovascular disorders such as sudden death, QT prolongation and Torsades des Points.

Precautions: In epilepsy and Parkinson's. Liver and kidney failure, pregnancy, lactation, cardiovascular diseases, depression of the central nervous system.

Interactions

It may lower the seizure threshold in patients receiving antiepileptics. With antimuscarinics, adverse effects increase. With lithium it can cause encephalopathy. With antiparkinsonian drugs, the therapeutic effects decrease.

HYDROMORPHONE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Moderate to severe pain	Oral.
	Each tablet contains: Hydromorphone hydrochloride 2 mg.	from: Major surgery. Cancer.	Adults:

	Burns.	2 mg to 4 mg every 4 to 6 hours
040.000.2113.00 Contai her with 100 tablets.	Renoreteral and biliary colic.	according to the patient's response.
	Acute myocardial infarction.	
	Multiple	
	trauma patients.	
1	trauma patients.	
	Generalities	
Narcotic opiate agonist that acts by selectively inhibitir	ng the release of neurotransr	mitters from the afferent nerve terminals
that produce painful stimuli.		
Risk in Pregnancy	С	
<u></u>		_
	Adverse effects	
Respiratory depression, vomiting, muscle rigidity, eupl	horia, bronchoconstriction, o	rthostatic arterial hypotension, miosis,

bradycardia, confusion, dizziness, anxiety, drowsiness and seizures.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug and opioids, treatment with monoamine oxidase inhibitors, head trauma, intracranial hypertension and respiratory dysfunction, cardiac arrhythmias, psychosis and hypothyroidism.

Precautions: Children under 12 years of age.

Interactions

Associated with benzodiazepines and alcohol it produces respiratory depression. Monoamine oxidase inhibitors, antihypertensives and diuretics enhance its hypotensive effects, with anticholinergics it causes severe abdominal distention.

HYPROMELLOSE

Clue	Description	Indications	Route of administration and dosage
	0.5% OPHTHALMIC SOLUTION	Associated eye irritation	Ophthalmic.
		with poor tear production.	
	Each mL contains:		Adults:
	Hypromellose 5r	ng	
		Lubricant and protector of the	2% solution: 1 to 2 drops, which can be repeated at the discretion of the
010.000.2814.00	Container with integral dropper with 15 mL.	eyeball.	specialist and depending on the case.
			Children:
			0.5% solution: 1 to 2 drops, which can be repeated
			at the discretion of the specialist and according to the
			case.
		Generalities	

Lubricates the ocular conjunctiva.

Risk in Pregnancy

Adverse effects

Transient blurred vision, mild irritation, edema, hyperemia.

Contraindications and Precautions

Contraindications: Hypersensitivity to the $\overline{\text{drug.}}$

Interactions

None of clinical importance.

IBUPROFENE

DOI I TOI LIVE			
Clue	Description	Indications	Route of administration and dosage
	TABLET OR CAPSULE	Mild to moderate pain.	Oral.
		Fever.	
	Each tablet or capsule contains: Ibuprofen		Adults and kids older than 12 years old.
	200 mg.		200 to 400 mg every 4 to 6 hours, depending on the
			intensity of symptoms, without exceeding 1200 mg per
010.000.5940.02	Package with 20 tablets or capsules.		day.
010.000.5940.03	Container with 30 capsules.		

	TABLET OR CAPSULE	l Oral.
	TABLET OR GAI GOLE	Olai.
	Each tablet or capsule contains:	Adults and kids older than 12 years old.
	Ibuprofen 400 mg.	400 mg every 6 to 8 hours, depending on the
	ibuproteri 400 mg.	intensity of the symptoms, without exceeding
010.000.5941.01	Package with 12 tablets.	1200 mg per day.
010.000.5941.01		
010.000.5941.02	Container with 20 capsules.	
010.000.0041.00	Container with 30 capsules. ORAL SUSPENSION	Oral.
	ORAL SUSPENSION	Olai.
	Each 100 mL contains:	Children from 6 months to 12 years of age:
	Ibuprofen 2 g.	From 5 to 10 mg/kg body weight / dose, depending on
010.000.5943.00		the intensity of pain and fever administered every 6 or 8 hours.
010.000.5943.00	Container with 120 mL and measuring measure.	nours.
1	ORAL SUSPENSION	
	Each milliliter contains:	
	Ibuprofen 40 mg.	
010.000.5944.00	l	
010.000.5944.00	15 mL container with a calibrated	
	dropper, integrated or attached to	
	the container that serves as a lid.	

Generalities

It is a prostaglandin inhibitor drug that manages through this mechanism of action to control inflammation, pain and fever. The antiprostaglandin action is through its inhibition of cyclooxygenase responsible for the biosynthesis of prostaglandins.

Risk in Pregnancy	Х
<u> </u>	·
Adverse	e effects

Epigastric pain, nausea, dizziness, heartburn, sensation of fullness in the gastrointestinal tract, thrombocytopenia, skin rashes, headache, blurred vision, toxic amblyopia, fluid retention.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug

Precautions: History of: ulcerative colitis, Crohn's disease; history of HTN and/or heart failure; bronchial asthma; hematopoietic disorders, systemic lupus erythematosus or mixed connective tissue disease. The risk of gastrointestinal bleeding, ulcer or perforation is greater when increasing doses of NSAIDs are used, in patients with a history of ulcer and over 65 years of age. Assess risk/benefit in: HTN, CHF, established coronary artery disease, peripheral arterial disease and/or cerebrovascular disease, acute intermittent porphyria. In long-term treatment with known cardiovascular risk factors (HTN, hyperlipidemia, diabetes mellitus, smokers). Control of those undergoing major surgery. Renal, hepatic and hematological control. Risk of skin reactions at the beginning of treatment.

Use minimum effective dose for the shortest time possible to minimize adverse reactions.

Interactions	

Reduces effectiveness of: furosemide, thiazide diuretics. Reduces hypotensive effect of: ß-blockers, ACE inhibitors. Reduces effect of: mifepristone. Increases plasma levels of: digoxin, phenytoin and lithium. Increases toxicity of: methotrexate, hydantoins, sulfonamides. Potentiates gastrointestinal lesions with: salicylates, phenylbutazone, indomethacin and other NSAIDs. Increases effect of: oral hypoglycemic agents and insulin. Additive effect on platelet inhibition with: ticlopidine. Increases risk of hematotoxicity with: zidovudine. Power bleeding time of: anticoagulants. Increases risk of nephrotoxicity with: tacrolimus, cyclosporine. Increased risk of bleeding and gastrointestinal ulcer with: corticosteroids, bisphosphonates or oxypentiphylline, selective cyclooxygenase-2 inhibitors. Risk of bleeding with: herbal extracts.

IMIPRAMINE

Clue	Description	Indications	Route of administration and dosage
	DRAGEE OR TABLET	Depression	Oral.
040.000.3302.00	Each dragee or tablet contains: Imipramine Hydrochloride 25 mg. Package with 20 dragees or tablets.	Enuresis.	Adults: 75 to 100 mg/day divided every 8 hours, increasing according to therapeutic response from 25 to 50 mg until reaching 200 mg. Children 6 years and older:
			25 mg one hour before bed.

It increases the amount of norepinephrine, serotonin or both in the central nervous system, blocking their reabsorption, thereby preventing the accumulation of these neurotransmitters. Risk in Pregnancy d Adverse effects Insomnia, sedation, dry mucous membranes, dizziness, constipation, blurred vision, hypotension or high blood pressure, tachycardia, dysuria. Contraindications and Precautions Contraindications: Hypersensitivity to the drug or tricyclic antidepressants. Precautions: In cardiovascular conditions, prostatic hypertrophy, glaucoma, hyperthyroidism, epilepsy and seizure syndrome. Interactions With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances depression caused by alcohol.					
thereby preventing the accumulation of these neurotransmitters. Risk in Pregnancy Adverse effects Insomnia, sedation, dry mucous membranes, dizziness, constipation, blurred vision, hypotension or high blood pressure, tachycardia, dysuria. Contraindications and Precautions Contraindications: Hypersensitivity to the drug or tricyclic antidepressants. Precautions: In cardiovascular conditions, prostatic hypertrophy, glaucoma, hyperthyroidism, epilepsy and seizure syndrome. Interactions With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
Adverse effects Insomnia, sedation, dry mucous membranes, dizziness, constipation, blurred vision, hypotension or high blood pressure, tachycardia, dysuria. Contraindications and Precautions Contraindications: Hypersensitivity to the drug or tricyclic antidepressants. Precautions: In cardiovascular conditions, prostatic hypertrophy, glaucoma, hyperthyroidism, epilepsy and seizure syndrome. Interactions With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
Insomnia, sedation, dry mucous membranes, dizziness, constipation, blurred vision, hypotension or high blood pressure, tachycardia, dysuria. Contraindications and Precautions Contraindications: Hypersensitivity to the drug or tricyclic antidepressants. Precautions: In cardiovascular conditions, prostatic hypertrophy, glaucoma, hyperthyroidism, epilepsy and seizure syndrome. Interactions With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
Insomnia, sedation, dry mucous membranes, dizziness, constipation, blurred vision, hypotension or high blood pressure, tachycardia, dysuria. Contraindications and Precautions Contraindications: Hypersensitivity to the drug or tricyclic antidepressants. Precautions: In cardiovascular conditions, prostatic hypertrophy, glaucoma, hyperthyroidism, epilepsy and seizure syndrome. Interactions With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
Contraindications and Precautions Contraindications: Hypersensitivity to the drug or tricyclic antidepressants. Precautions: In cardiovascular conditions, prostatic hypertrophy, glaucoma, hyperthyroidism, epilepsy and seizure syndrome. Interactions With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
Contraindications: Hypersensitivity to the drug or tricyclic antidepressants. Precautions: In cardiovascular conditions, prostatic hypertrophy, glaucoma, hyperthyroidism, epilepsy and seizure syndrome. Interactions With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
Contraindications: Hypersensitivity to the drug or tricyclic antidepressants. Precautions: In cardiovascular conditions, prostatic hypertrophy, glaucoma, hyperthyroidism, epilepsy and seizure syndrome. Interactions With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
Precautions: In cardiovascular conditions, prostatic hypertrophy, glaucoma, hyperthyroidism, epilepsy and seizure syndrome. Interactions With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
Precautions: In cardiovascular conditions, prostatic hypertrophy, glaucoma, hyperthyroidism, epilepsy and seizure syndrome. Interactions With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
With monoamine oxidase inhibitors, adverse effects increase. It can block the effect of guanethidine and clonidine; enhances					
depression caused by alcohol.					
· · · · · · · · · · · · · · · · · · ·					
NDOMETHACIN					
Clue Description Indications Route of administration and dosage					
SUPPOSITORY Anti-inflammatory in Rectal. acute and chronic articular					
Each suppository contains: or periarticular processes. Adults:					
100 mg twice a day.					
D10.000.3412.00 Container with 6 suppositories. CAPSULE Utero-inhibitor. Oral.					
A440-					
Each capsule contains: Indomethacin 25mg Adults:					
25 to 50 mg three times a day.					
Container with the capealed.					
Generalities					
It produces its anti-inflammatory, analgesic and antipyretic effect by inhibiting the synthesis of prostaglandins.					
Risk in Pregnancy B/D in third trimester					
Adverse effects					
Nausea, vomiting, epigastric pain, diarrhea, headache, vertigo, hypersensitivity reactions, gastrointestinal bleeding.					
Contraindications and Precautions					
Contraindications: Hypersensitivity to the drug and NSAIDs, breastfeeding, gastrointestinal bleeding, epilepsy, Parkinson's					
disease, psychiatric disorders, bronchial asthma, children under 14 years of age and anorectal conditions.					
Interactions					
It increases the toxicity of lithium, reduces the effects of furosemide and increases the effect of anticoagulants and hypoglycemics.					

KETOROLAC

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Pain of mild to moderate intensity.	Intramuscular or intravenous.
	Each vial or vial contains:		Adults:
	Ketorolac-tromethamine 30 mg.		30 mg every 6 hours, maximum dose 120 mg/day.
010.000.3422.00	Package with 3 vials or 3 1 mL vials.		Treatment should not exceed 4 days.
			Children:
			0.75 mg/kg body weight every 6 hours. Maximum dose 60 mg/day. Treatment should not exceed 2 days.

]	Gener	alities	1
It inhibits the enzyme cyclooxygenase and	d therefore the synth	hesis of prostaglandin	S.
Risk in Pr	egnancy	С	
1	Adverse	e effects	1
Peptic ulcer, gastrointestinal bleeding, interpaleness, high blood pressure, dysgeusia		oruritus, nausea, dysp	epsia, anorexia, depression, hematuria,
]	Contraindications	s and Precautions	1
Contraindications: Hypersensitivity to the failure and hemorrhagic diathesis, postop	•		, , , , ,
[Intera	ctions]
Synargism with other non-steroidal anti-in	flammatory druge to	increase the rick of a	dvarca affacts Decreases the diviration

response to furosemide. Probenecid increases its plasma concentration. Increases plasma lithium concentration.

LAMOTRIGINE

Clue	Description	Indications	Route of administration and dosage
010.000.5356.00	TABLET Each tablet contains: Lamotrigine 100 mg. Package with 28 tablets.	Epilepsy.	Oral. Adults: Start with 25 mg/day, for 2 weeks, increase to 50 mg for 2 weeks and from the 5th week, administer a maintenance dose of 100 to 200 mg per day, or divided every 12 hours.
			Children: Start with 2 mg/kg/day, divide the dose every 12 hours for 2 weeks, then 5 mg/kg/day for 2 more weeks and finally 5 to 15 g/kg/day as a maintenance dose.

Generalities

Sodium channel blocker, produces voltage-dependent blockade of sustained repetitive discharge in neurons and inhibits the pathological release of glutamate. It also inhibits action potentials caused by glutamate.

Risk in Pr	egnancy c			
	Adverse effects			
leadache, fatigue, rash, nausea, dizziness, drowsiness, insomnia.				
	Contraindications and Precautions			
Contraindications: Hypersensitivity to the drug.				
	Interactions			

Antiepileptic agents (phenytoin, phenobarbital, carbamazepine and pidone), and inducers of hepatic enzymes that metabolize other drugs, increase the metabolism of lamotrigine.

LEVETIRACETAM

Clue	Description	Indications	Route of administration and dosage
	TABLET	Epilepsy as concomitant therapy in partial-onset seizures with or	Oral.
	Each tablet contains:	without generalization	Adults:
	Levetiracetam 500 mg.	secondary.	1,000 to 3,000 mg daily in divided doses every 12 hours.
010.000.2617.00	Package with 60 tablets.		
	TABLET	Myoclonic epilepsy.	
	Each tablet contains: Levetiracetam 1,000 mg.	Generalized epilepsy primary.	
010.000.2618.00	Package with 30 tablets.		
	ORAL SOLUTION]	Oral.

010.000.2616.00	Each 100 mL contains:	Children from 4 to 12 years:
	Levetiracetam 10g.	Initial dose of 10 mg/Kg of weight, each
		12 hours, depending on the clinical response and
	Container with 300 mL.	presence of adverse reactions, up to 30 mg/
	(100 mg/mL).	Kg of weight can be administered every 12 hours.

Generalities

The exact mechanism by which it exerts its antiepileptic effect is unknown, but it does not seem to derive from any interaction with known mechanisms that participate in inhibitory and excitatory neurotransmission.

> Risk in Pregnancy Adverse effects

Drowsiness, asthenia, dizziness, vertigo, convulsion, depression, emotional lability, hostility, insomnia, nervousness, ataxia, tremor, amnesia. Accidental injury due to decreased neuromuscular reflexes, headache, nausea, dyspepsia, diarrhea, anorexia, skin rash, diplopia.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug and other pyrrolidone derivatives or to any of the components of the formula. Do not use during pregnancy or lactation.

Precautions: In severe liver failure, administer a 50% dose. In renal failure, dose according to creatinine clearance. In children under 16 years of age it is advisable to administer the oral solution presentation.

Interactions

Probenecid inhibits renal clearance of the primary metabolite of levetiracetam. It does not influence the serum concentrations or clinical efficacy of other antiepileptic drugs (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and pidone) and these drugs do not influence the pharmacokinetics of levetiracetam. It also does not modify the pharmacokinetics of coumarin anticoagulants, oral contraceptives and digoxin.

LEVOMEPROMAZINE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Psychosis with anxiety or	Oral.
		extreme agitation	
	Each tablet contains: Maleate		Adults and kids older than 12 years old:
	levomepromazine equivalent to 25 mg of		12.5 to 25 mg/day, or divided every 8 hours.
	levomepromazine.		
	Package with 20 tablets.		
040.000.3204.00			

Generalities

Competitive antagonist of dopamine receptors of the limbic system, thalamus and hypothalamus.

Risk in Pregnancy

Adverse effects Dry mucous membranes, drowsiness, arterial hypotension, urinary retention, parkinsonism, akathisia, dyskinesia,

photosensitivity, cholestatic jaundice, blood dyscrasias, hyperprolactinemia.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug or phenothiazines, liver failure, kidney failure, untreated epilepsy, arterial hypotension, bone marrow depression, coma, Parkinson's disease.

Interactions

Intensifies and prolongs the action of opiates, analgesics, alcohol, diphenylhydantoin and other depressants of the central nervous system. With antihypertensives they increase orthostatic hypotension. With antimuscarinics the effects increase adverse.

LORAZEPAM

Clue	Description	Indications	Route of administration and dosage
	TABLET	Anxiety.	Oral.
	Each tablet contains:	Anxious neurosis or	Adults:
	Lorazepam 1 mg.	caused by organic disorders.	
			2 to 4 mg/day, divided every 8 or 12 hours.
040.000.5478.00	Package with 40 tablets.		
		emotional tension.	

				1	
			Insomnia.		
			Generalities		
Promotes GABAergio	activity. Suppresses the seizure activi				
	Promotes GABAergic activity. Suppresses the seizure activity of epileptogenic foci in the cortex, thalamus and limbic structures.				
	Risk in Pregnan	ncv	d		
				7	
Hyporoflovia atavia	drowsiness, apnea, respiratory failure		dverse effects		
турогенска, акака,	drowsiness, aprica, respiratory failure,	, асргоза	on or consciousness, dependence	and totalice.	
		ntraindi	cations and Precautions	٦	
	s: Hypersensitivity to the drug a	and benz	odiazepines.	_	
Precautions: In g	laucoma, respiratory failure, liv	er failur	e, kidney failure, myasthenia	a gravis.	
			Interactions]	
	s administration of barbiturates	s, ingesti	on of alcohol and other ben	zodiazepines increases the	
depressive effect	5.				
<u>MEGESTRO</u>			Indications	-	
Clue	Description TABLET		Breast cancer.	Route of administration and dosage Oral.	
	Each tablet contains:		Endometrial cancer.	Adults:	
	Megestrol acetate 40	Omg			
010.000.5430.00	Package with 100 tablets.			Breast: 40 mg, every 6 hours. Endometrium: 20 to 80 mg every 6 hours	
			Generalities	 7	
Progestogen that i	inhibits the pituitary and produces			_	
	· · ·		d		
	Risk in Pregnan	ncy	a		
			dverse effects]	
Weight gain, fluid	retention, high blood pressure	e, mensti	rual disorders.		
			cations and Precautions]	
	to the drug and progestogens. It epilepsy, diabetes mellitus, kid			nistory of thromboembolism and	
unombopniebius,	epilepsy, diabetes mellitus, kit	uriey dis		ame.	
MC4b b a man a sala a s			Interactions		
vvitn normonal co	ontraceptives the risk of thromb	oebolisi	n increases. Interferes with	the effect of bromocriptine.	
<u>MELOXICAN</u>	1				
Clue	Description TABLET		Indications Rheumatoid arthritis.	Route of administration and dosage Oral.	
	Each tablet contains:		Osteoarthritis.	Adulta and page a year 12 years ald	
	Meloxicam 15m	ng		Adults and people over 12 years old:	
			Spondylitis.	15 mg every 24 hours.	
010.000.3423.00	Package with 10 tablets.		Gouty arthritis.	Children:	
			Acute and chronic	Maximum dose: 0.25 mg/kg body weight/day.	
			non-rheumatic inflammatory conditions.		
			Acute nonbacterial		
			inflammatory processes of the		
			upper airways.		
			Generalities	J _	
Non-steroidal anti-inflammatory drug of the oxicam family, which selectively inhibits cyclooxygenase 2 (COX-2).					

Risk in Pregnancy

	Adverse effects	
Hypersensitivity reaction, diarrhea, abdom ulceration and perforation in the gastrointe		e. It can cause bleeding due to erosion
	Contraindications and Precautions	
Contraindications: Hypersensitivity to the c	drug and acetyisalicylic acid, gastrointestii	nai irritation, peptic uicer.
	Interactions	
Decreases the antihypertensive effect of A	CF inhibitors and beta blockers. With cho	plestyramine its absorption decreases

Decreases the antihypertensive effect of ACE inhibitors and beta blockers. With cholestyramine its absorption decreases. With other NSAIDs, adverse effects increase. May increase the effects of anticoagulants and methotrexate. With diuretics it can cause acute renal failure.

METHADONE

Clue	Description	Indications	Route of administration and dosage
	SOLUTION	Relief from severe pain.	Oral.
	Each milliliter contains:		Adults.
	Methadone Hydrochloride 10 mg.		Dose 5 to 20 mg every 4 to 8 hours, being able to modify the dose as well as the administration
040.000.5910.00	Container with 30 mL and 1 mL dropper.		time interval according to the patient's analgesic needs from every 8 to 12 hours.

Generalities

Pure opiate agonist of synthetic origin, with slightly greater potency than morphine, longer duration of action, and less euphoric effect. It presents affinity and marked activity at μ receptors.

Risk in Pregnancy	С
	Adverse effects

Dizziness, sedation, nausea and vomiting. Others include mental confusion, drowsiness, lethargy, decreased psychic and mental abilities, anxiety, delusions, changes in emotional status, urethral and bladder sphincter spasm, urinary retention, pruritus, skin rash, and respiratory depression. Long-term use causes constipation more frequently than other opioids.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug. Events presenting respiratory depression, head trauma, intracranial hypertension, acute abdominal pain, acute alcohol poisoning (delirum tremens), in combination with central nervous system depressant medications, pregnancy and lactation.

Caution: In patients at risk of QT prolongation (cardiac hypertrophy, use of diuretics, hypokalemia, hypomagnesemia), elderly patients, alterations in renal and/or liver function, Adison's disease, prostatic hypertrophy, pulmonary disease, postoperative period operative, handling of precision machinery, cancer,

medications that affect serum concentrations of alpha 1 acid glycoprotein, elderly.

Interactions

Exacerbation of the effects of methadone with the use of CNS depressant medications, alcohol. The combination of agents with an anticholinergic effect increases the risk of severe abdominal distention, which may cause paralytic ileus and/or urinary retention. Coadministration of drugs that inhibit CYP3A4 activity such as antifungal agents (ketoconazole) may result in decreased methadone tapering. Monoamine oxidase (MAO) inhibitors may increase the risk of hypertension or hypotension, respiratory depression, and cardiovascular collapse. Arterial hypotension with the concomitant use of antihypertensives and diuretics. Selective serotonin reuptake inhibitors (SSRIs) increase methadone toxicity. Urinary cidifiers, anticonvulsants (phenytoin, phenobarbital), enzyme inducers and antivirals (zidovudine) increase the risk of withdrawal syndrome.

METAMIZOLE SODIUM

IL I AMILOLL GODIOM				
Clue	Description Indications		Route of administration and dosage	
	COMPRESSED	Fever.	Oral.	
	Each tablet contains: Metamizole sodium 500 mg.	Acute or chronic pain	Adults:	
010.000.0108.00	Package with 10 tablets.	Some cases of visceral pain.	500-1000 mg every 6 or 8 hours.	
	INJECTABLE SOLUTION		Intramuscular or intravenous.	

010.000.0109.00	Each vial contains: Metamizole sodium Container with 3 vials with	1g. 2 mL.		Adults: 1 g every 6 or 8 hours by deep intramuscular route. 1 to 2 g every 12 hours intravenously.	
Generalities It inhibits the synthesis of prostaglandins and acts on the thermoregulatory center in the hypothalamus. Risk in pregnancy x					
Adverse effects Hypersensitivity reactions: agranulocytosis, leukopenia, thrombocytopenia, hemolytic anemia.					
Contraindicated: Hypersensitivity to the drug and pyrazolones. Kidney or liver failure, blood dyscrasias, duodenal ulcer.					
Precautions: Do not administer for long periods. Hematological assessment during treatment. It is not recommended in children.					
Interactions With neuroleptics it can cause severe hypothermia.					

METHYLPHENIDATE

Clue	Description	Indications	Route of administration and dosage
	COMPRESSED	Narcolepsy. Attention deficit hyperactivity	Oral.
	Each tablet contains:	disorders.	Adults:
	Methylphenidate hydrochloride 10 mg		20 to 30 mg every 8 to 12 hours.
			Maximum dose 60 mg/day.
040.000.5351.00	Package with 30 tablets.		Children:
			5 mg every 8 to 12 hours, increase the
			dose (5 mg) until the therapeutic effect
			is achieved.
			Maximum dose 50 mg/day.

CNS stimulant that decreases motor activity and increases mental activity.

Risk in Pregnancy

Adverse effects

Headache, stomach pain, loss of appetite, insomnia, vomiting, blurred vision.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, anxiety, glaucoma, hypertension, epilepsy.

Precautions: history or diagnosis of Tourette syndrome, hematological monitoring in prolonged treatment.

Pharmacological studies in humans have shown that methylphenidate can inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, phenytoin, pidone) and some antidepressants (tricyclics and selective serotonin reuptake inhibitors). Reductive dosage adjustment of these drugs may be required when administered concomitantly with methylphenidate.

Interactions

MIRTAZAPINE

Clue	Description	Indications	Route of administration and dosage
	TABLET OR TABLET DISPERSABLE	Depression.	Oral
			Adults:
	Each tablet or dispersible tablet contains:		
			30 mg every 24 hours.
	Mirtazapine 30 mg		
010.000.5490.00			

	Package with 30 tablets or disp tablets.	persible		
			Generalities	
It is a presynaptic	antagonist of alpha recep	tors.		
	Risk in Pr	egnancy	d	_
			dverse effects]
Increased appetite	e and weight gain, drowsin	ess, orthostation	c hypotension, mania, seizure	s, edema, acute bone marrow depression.
		Control	vations and Proceed's se	1
Contraindications	: Hypersensitivity to the dru		ations and Precautions der 18 years of age.	_
			Interactions	7
			d also the sedative action of a	Icohol on the central nervous system. It should eks of stopping therapy with these agents.
MORPHINE	1		I Indications	Pouto of administration and decree
Clue	Description INJECTABLE SOLUTION	1	Acute or chronic pain	Route of administration and dosage Intravenous, intramuscular or epidural.
	Each vial contains:		moderate to intense caused by:	Adults:
	morphine sulfate Pentahydrate	2.5 mg.	Cancer (preterminal and	5 to 20 mg every 4 hours, depending on therapeutic
040.000.2099.00	Container with 5 vials with 2		terminal phase).	response.
	INJECTABLE SOLUTION	•	Acute myocardial infarction.	Epidural: 0.5 mg, followed by 1-2 mg until
	Each vial contains:			10 mg/day.
	Morphine sulfate pentahydrate	50 mg.	In the control of postsurgical	Children: 0.05-0.2 mg/kg every 4 hours up to 15 mg.
040.000.2102.00	Container with 1 vial with 2.	0 mL.	pain in polytraumatized patients and	Requires a narcotic prescription.
	INJECTABLE SOLUTION		in those with burns.	
	Each vial contains: morphine sulfate	10 mg.		
040.000.2103.00	Container with 5 vials.		_	Oral
	TABLET			Oral.
	Each tablet contains: Morphine sulfate pentahydrate to 30 mg of morphine sulfate.	equivalent		Adults: 30 to 60 mg every 8 to 12 hours.
040.000.4029.00	Package with 20 tablets.			
	J		Generalities	, 7
• •	the μ and ÿ receptors. Its a K at the level of the spinal	analgesic effect	t has been related to the activ	∟l ation of μ receptors
22-22-2000, 2010	· ·		h	
	Risk in Pr	egnancy	b	-
	ession, nausea, vomiting, uures and addiction.	9	dverse effects ria, sedation, bronchoconstric	tion, orthostatic arterial hypotension, miosis,
		Contraindic	ations and Precautions]
	ypersensitivity to the drug, treat arrhythmias, psychosis, hypoth	ment with monoar	mine oxidase inhibitors, traumatic b	rain injury, intracranial hypertension and respiratory
		<u> </u>	Tatan d	7
			Interactions	_

Associated with benzodiazepines, cimetidine, phenothiazines, hypnotics, neuroleptics and alcohol, it produces respiratory depression. Monoamine oxidase inhibitors enhance the effects of morphine.

NALOXONE

Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Opiate poisoning.	Intramuscular, intravenous, subcutaneous.
	Each vial contains: Naloxone		Adults:
	hydrochloride 0.4 mg.		0.4 to 2 mg every 3 minutes, until the therapeutic effect
040.000.0302.00	Container with 10 vials with 1 mL.		is obtained. Maximum dose 10 mg/day.
			Children:
			0.4 mg/kg hody unight/door Apply doors gyory 2
			0.1 mg/kg body weight/dose. Apply doses every 3 minutes, until obtaining a clinical response.
			1
	*	Generalities	200

Competitive antagonism with previously administered narcotic analgesics. It has no pharmacological activity by itself.

Risk in Pregna	ancy b
	Adverse effects
Systemic arterial hypotension, tachycardia, na	ausea, vomiting, diaphoresis, fasciculations, pulmonary edema, irritability.
	Contraindications and Precautions
Contraindications: Hypersensitivity to the med	dication.
	Interactions

METHOCARBAMOL

None of clinical importance.

Clue	Description	Indications	Route of administration and dosage
010.000.3444.00	TABLET Each tablet contains: Methocarbamol 400mg Package with 30 tablets.	Adjuvant in disorders Acute painful skeletal muscles.	Oral. Adults and kids older than 12 years old: 2 tablets every 6 hours.

Generalities

Relaxant of skeletal muscle, reduces the transmission of impulses from the spinal cord to skeletal muscle.

Risk in Pregnancy C

Adverse effects

Dizziness, nausea, drowsiness, bradycardia, arterial hypotension, headache, fever and allergy manifestations.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, myasthenia gravis.

Interactions

With alcohol, anxiolytics, antipsychotics, opiates, tricyclic antidepressants and central nervous system depressants (CNS), increases CNS depression.

Naproxen

1	Clue	Description	Indications	Route of administration and dosage
		TABLET	Acute pain and	Oral.
			inflammation.	
		Each tablet contains:		Adults:

	Naproxen	250mg	Rheumatoid arthritis.	500 to 1500 mg in 24 hours.
40 000 0457 00	·	20011Ig		Oral.
10.000.3407.00	Package with 30 tablets. ORAL SUSPENSION		Osteoarthritis.	Children:
	ORAL SUSPENSION		Ankylosing spondylitis.	10 mg/kg body weight initial dose, followed by
	Each 5 mL contains:		runtylooning aportayinto.	2.5 mg/kg body weight every 8 hours. Maximum
	Naproxen	125mg	Tendinitis.	dose 15 mg/kg body weight/day.
10.000.3419.00	Container with 100 mL.		Bursitis.	
			Generalities	
Its anti-inflamma	tory, analgesic and antipyre	etic effect is p	robably due to the inhibition	of prostaglandin synthesis.
	Risk in Pre	egnancy	b	
	ļ		Adverse effects	
Nausea, gastric i steroids.	rritation, diarrhea, vertigo, l	headache, cro	oss-hypersensitivity with aspi	rin and other non-inflammatory drugs.
		Contraind	cations and Precautions	
Contraindications	: Hypersensitivity to the dr	ug, gastrointe	estinal bleeding, peptic ulcer,	kidney and liver failure, lactation.
	ľ		Interactions	7
It competes with	oral anticoagulante, sulfon	vlureae and a		oteins. It increases the action of insulins and
•	nd antacids decrease their	•	moonvuisanis ioi piasina pit	none. It increases the action of mounts and
nypogiyochilos di	וש מוונעטועט עבטובמטב נוופוו	aboorpuur.		
1 117171	ır			
LANZAPIN	1		Indiactions	1
Clue	Description TABLET	1	Indications	Route of administration and dosage
	TABLET		Schizophrenia.	Oral.
	Each tablet contains:			Adults:
	Olanzapine	5mg		1
040 000 5 105 00		ŭ		5 to 20 mg, every 24 hours.
010.000.5485.00 010.000.5485.01	Package with 14 tablets. Package with 28 tablets.			
0.10.000.0400.01	TABLET		┥	
	Each tablet contains:			
	Olanzapine	10mg		
010.000.5486.00	Package with 14 tablets.		1	
010.000.5486.01	Package with 28 tablets.			1
	INJECTABLE SOLUTION		Agitation associated with:	Intramuscular.
	Each vial with lyophilisate contain	ns:	Schizophrenia.	Adults:
	Olanzapine	10mg	Bipolar illness.	2.5 mg in agitated patients with dementia.
010.000.4489.00	Container with a vial.	Tomy	Dementia.	10 mg in agitated patients with
	T COIRMINE WILL & VIAL.		!	schizophrenia or bipolar illness.
			Generalities	
Thienobenzodiazepi	ne with affinity for various recep	otors such as: do	ppaminergic, serotonergic, histami	nergic and muscarinic.
	Risk in Pre	egnancy	x	
	ſ		Adverse effects	
	l l			
Drowsiness, incre	ا ease in body weight, vertiq	o, akathisia, e	edema, increased appetite, or	thostatic hypotension, dry mouth, constipation
Drowsiness, incre	l ease in body weight, vertig	o, akathisia, e	edema, increased appetite, or	thostatic hypotension, dry mouth, constipation
Drowsiness, incre	ا ease in body weight, vertigo ا			rthostatic hypotension, dry mouth, constipatio
		Contraind	edema, increased appetite, or cations and Precautions	thostatic hypotension, dry mouth, constipatio
Contraindications	s: Hypersensitivity to the dr	Contraind		rthostatic hypotension, dry mouth, constipatio
Contraindications		Contraind		rthostatic hypotension, dry mouth, constipatio
Contraindications	s: Hypersensitivity to the dr	Contraind		thostatic hypotension, dry mouth, constipatio

Its elimination is increased by carbamazepine and tobacco smoke. Ethanol can cause additive effects and activated carbon considerably reduces its absorption.

ONDANSETRON

Clue	Description	Indications	Route of administration and dosage
	TABLET	Nausea and vomiting secondary to	Oral.
	Each tablet contains:	antineoplastic	Adults:
	Ondansetron hydrochloride	chemotherapy	One tablet every 8 hours, one to two hours before
	dihydrate equivalent to 8 mg of ondansetron.	and radiotherapy.	radiotherapy. The treatment can be for five days.
010.000.2195.00	Package with 10 tablets.		Children over four years old: Half a tablet every eight hours for five days.
	INJECTABLE SOLUTION	-	Slow intravenous or infusion.
	Each vial or vial contains:		Adults:
	Ondansetron hydrochloride		One vial, 15 minutes before chemotherapy. Repeat 4
	dihydrate equivalent to 8 mg of ondansetron.		and 8 hours after the first dose.
010.000.5428.00	Container with 3 vials or vials with 4 mL.		Intravenous infusion: 1 mg/hour up to 24 hours.
			Children over four years old: 5 mg/m2 of body surface, for fifteen minutes immediately before chemotherapy.
			Administer diluted in intravenous solutions packaged in glass bottles.

Generalities

Selective serotonin antagonist at the level of three receptors that reduces the incidence and severity of nausea and vomiting induced by various cytotoxic drugs.

Risk in Pr	regnancy b
	Adverse effects
Headache, diarrhea, constipation and hyp	persensitivity reactions.
	Contraindications and Precautions
Contraindications: Hypersensitivity to the Precautions: Assess risk benefit in breast	•
İ	Interactions

Inducers or inhibitors of the hepatic microsomal enzyme system modify its transformation.

OXYCODONE

Clue	Description	Indications	Route of administration and dosage
	RELEASE TABLET	Severe pain secondary to	Oral.
	PROLONGED	ailments:	
			Adults:
	Each tablet contains:	Osteoarticular.	
	Oxycodone hydrochloride 20 mg.		Take 10 to 20 mg every 12 hours.
		Chronic muscles.	Increase the dose according to the intensity of the pain
040.000.4032.00	Package with 30 prolonged release tablets.		and at the discretion of the specialist.
		Cancer.	
040.000.4032.01	Package with 100 extended-release		
	tablets.		
	RELEASE TABLET		
	PROLONGED		
	Each tablet contains:		
	Oxycodone hydrochloride 10 mg.		
040.000.4033.00	Package with 30 prolonged release tablets.		
040.000.4033.01	Package with 100 extended-release		
0.0.000.7000.01			
	tablets.		1

Generalities

Opioid agonist, with pure action on the \ddot{y} , \ddot{y} and \ddot{y} opioid receptors of the brain and spinal cord. The effect Therapeutic is mainly analgesic, anxiolytic and sedative.

Risk in Pregnancy C

Adverse effects

Respiratory depression, apnea, respiratory arrest, circulatory depression, arterial hypotension, constipation, constipation, nausea, vomiting, drowsiness, vertigo, pruritus, headache, anxiety, shock and physical dependence.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, respiratory depression, bronchial asthma, hypercapnia, paralytic ileus, acute abdomen, acute liver disease. Known sensitivity to oxycodone, morphine, or other opioids.

Precautions: Pregnancy and lactation, seizure disorders.

Interactions

They enhance the effects of phenothiazines, tricyclic antidepressants, anesthetics, hypnotics, sedatives, alcohol, muscle relaxants and antihypertensives. Its effect decreases with: monoamine oxidase inhibitors.

PARACETAMOL

Clue	Description	Indications	Route of administration and dosage
	TABLET	Fever	Oral.
	Each tablet contains: Paracetamol 500 mg.	Acute or chronic pain	Adults:
010.000.0104.00	Package with 10 tablets.		250-500 mg every 4 or 6 hours.
	ORAL SOLUTION		Oral.
	Each mL contains: Paracetamol 100 mg.		Children:
010.000.0106.00	Container with 15 mL, dropper calibrated at 0.5 and 1 mL, integrated or attached to the container that serves as a lid.		10 to 30 mg/kg body weight, each 4 or 6 hours.
	SUPPOSITORY	1	Rectal.
	Each suppository contains: Paracetamol 100 mg.		Adults:
			300-600 mg every 4 or 6 hours.
010.000.0514.00	Container with 3 suppositories.		Children:
			From 6 to 12 years: 300 mg every 4 or 6 hours. From 2 to 6 years: 100 mg every 6 or 8 hours. Over 6 months to one year: 100 mg every 12 hours.

Generalities

It inhibits the synthesis of prostaglandins and acts on the thermoregulatory center in the hypothalamus.

Risk in Pregnancy

٥

Hypersensitivity reactions: skin rash, neutropenia, pancytopenia, hepatic necrosis, renal tubulonecrosis and hypoglycemia.

Contraindications and Precautions

Adverse effects

Contraindications: Hypersensitivity to the drug, liver dysfunction and severe renal failure. Precautions: No more than 5 doses should be administered in 24 hours or for more than 5 days.

Interactions

The risk of hepatotoxicity to paracetamol increases in alcoholic patients and in those who take metabolism-inducing medications such as: phenobarbital, phenytoin and carbamazepine. Metamizole increases the effect of oral anticoagulants.

PARACETAMOL

Clue	Description	Indications	Route of administration and dosage

010.000.5720.01 010.000.5720.02	INJECTABLE SOLUTION Each bottle contains: Paracetamol 500 mg. Container with four bottles with 50 mL. Container with ten bottles with 50 mL INJECTABLE SOLUTION Each bottle contains: Paracetamol 1 g. Container with four bottles with 100 mL.	Moderate to severe postoperative pain in children and adults in addition to opioids in whom the use of NSAIDs is contraindicated.	Intravenous. Adults, adolescents and children weighing more than 50 kg: 1g per dose every 4 hours up to four times a day. Adults, adolescents and children weighing less than 50 kg. 15 mg/Kg of body weight per dose up to four times a day. Full-term newborns and children up to 10
010.000.5721.02	Container with ten bottles with 100 mL.		Kg of weight. 7.5 mg/Kg of body weight per dose up to four times a day.

Generalities

The mechanism of the analgesic and antipyretic properties of paracetamol has not yet been established. The mechanism of action can have central and peripheral actions.

Risk in Pregnancy c

Adverse effects

Thrombocytopenia, tachycardia, nausea, vomiting, fulminant hepatitis, liver necrosis, liver damage, increased liver enzymes, anaphylactic shock, anaphylaxis, angioneurotic edema, erythema, redness, pruritus, rash, urticaria.

Contraindications and Precautions

Contraindications: hypersensitivity to the drug.

Precautions: It is recommended to use appropriate oral analgesic treatment as soon as this route of administration is possible. Doses higher than recommended carry a risk of very serious liver damage.

Interactions

Concomitant paracetamol with phenytoin may cause a decrease in the effectiveness of paracetamol and increase the risk of hepatotoxicity. Probenecid causes an almost 2-fold reduction in the clearance of paracetamol by inhibiting its conjugation with glucuronic acid. Salicylamide may prolong the elimination half-life (t1/2) of paracetamol. The concomitant use of paracetamol (4 g per day for at least 4 days) with oral anticoagulants may produce slight variations in INR values.

PREDNISONE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Addison's disease.	Oral.
	Each tablet contains:	Asthma.	Adults:
	Prednisone 5 mg	Nephrotic syndrome.	5 to 60 mg/day, single dose or every 8 hours. Sustaining dose according to the therapeutic response
010.000.0472.00	Package with 20 tablets.		and subsequently gradually decreased until the lowest
		Diseases inflammatory.	dose is reached according to the pharmacological effect
		illiaminatory.	Maximum dose: 250 mg/day.
		Autoimmune	3.00
		diseases.	Children:
			0.5 to 2 mg/kg body weight/day or 25 to
			60 mg/m2 body surface area, administered every 6 to 12 hours. Dose
			maximum: 40 mg/day.
			In nephrotic syndrome 80 mg/day.

Intermediate action glucocorticoid. It induces the transcription of RNA, promoting the synthesis of enzymes responsible for its effects.

Risk in Pregnancy b

Adverse effects

Posterior subcapsular cataract, adrenal hypoplasia, Cushing's syndrome, obesity, osteoporosis, gastritis, superinfections, glaucoma, hyperosmolar coma, hyperglycemia, muscle catabolism, delayed healing, delay

he growth.

Contraindication crisis, liver and I	s: Hypersensitivity to the drug, act	traindications and Precautions tive tuberculosis, diabetes mellitus	s, systemic infection, peptic ulcer, hypertensive
		Interactions	\neg
biotransformation ir	creases and with estrogens it decreases		and amphotericin B. With anticonvulsants, its hepatic decreases.
PREGABAL Clue	r	Indications	Route of administration and dosage
010.000.4356.00 010.000.4356.01	Description CAPSULE Each capsule contains: Pregabalin 75 mg Container with 14 capsules. Container with 28 capsules. CAPSULE Each capsule contains:	Partial epilepsy with or without secondary generalization. Neuropathic pain in adults.	Oral Adults and children over 12 years of age: Starting dose 75 mg every 12 hours with or without food. If well tolerated, maintain this dose long term.
010.000.4358.00 010.000.4358.01	Pregabalin 150 mg Container with 14 capsules. Container with 28 capsules.		
potentially displa analgesic and a norepinephrine a Risk in Pred Dizziness, drow Contraindication Precautions: Do medication affect	acing ÿ 3Hÿ-gabapentin. Two lines nticonvulsant activity. Additionally, and substance P. gnancy siness, peripheral edema, infection Con s: hypersensitivity to the drug, not drive, operate complex machinests your ability to perform these activity and, lorazepam.	s of evidence indicate that pregabate, pregabalin reduces the release of the rele	um channels in the central nervous system, alin binding to the ÿ2 site is required for f several neurotransmitters including glutamate y dangerous activities until it is known if this
Clue	Description TABLET	Indications Psychosis.	Route of administration and dosage Oral
010.000.5489.00	Each tablet contains: Quetiapine furnarate equivalent to 100 mg of quetiapine. Package with 60 tablets.		Adults: 100 to 150 mg every 12 hours.
		2 with respect to D2 is what contrib	D2 receptors). The combination of antagonism outes to the antipsychotic effect.
Mild asthenia, di	ry mouth, rhinitis, dyspepsia and c		

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug and in children under 16 years of age.	
Precautions: Avoid concomitant use with medications that act on the central nervous system and alco	ohol.

It is an atypical antipsychotic that interacts with a wide variety of neurotransmitter receptors. Coadministration with thioridazine increases the elimination of quetiapine.

RISPERIDONE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Chronic schizophrenia.	Oral.
	Each tablet contains:		Adults:
	Risperidone 2 mg		
040.000.3258.00	Package with 40 tablets.		1 to 2 mg every 12 hours. The maintenance dose is established
			according to the therapeutic response.
	ORAL SOLUTION		Oral
	Each milliliter contains:		Adults:
	Risperidone 1 mg.		
040.000.3262.00			First day 2 mg. Second day 4 mg.
040.000.3262.00	Container with 60 mL and dosing dropper.		Subsequent days 4-6 mg/day.
	INJECTABLE SUSPENSION	Schizophrenia.	Intramuscular.
	EXTENDED RELEASE		Adults:
	Each vial contains:	Schizoaffective disorders.	Adults.
	Risperidone 25 mg	Schizoanective disorders.	25 mg every two weeks.
	Triopendone 20 mg		Maximum dose 50 mg every two weeks.
040.000.3268.00	Container with vial and syringe prefilled with 2 mL of diluent.		

Antipsychotic antagonist of 5-HT2 serotonin and D2 dopamine receptors. Oral bioavailability 94%, biotransforms to an active "hydroxy" metabolite. Half-life of 22 hours.

Risk in Pregnancy X

Adverse effects

Acute dystonia, extrapyramidal syndrome and akathisia within the first two months of treatment. After months or years of treatment: perioral tremor and tardive dyskinesia. Neuroleptic malignant syndrome rarely occurs. Other effects include weight gain, sedation, postural hypotension, skin rashes, and blood dyscrasias.

Generalities

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug and bone marrow depression.

Precautions: In arterial hypotension and Parkinson's disease.

Interactions

It enhances the effects of other nervous system depressants such as sedatives, alcohol, antihistamines and opiates.

They inhibit the actions of dopamine agonists.

SERTRALINE

Clue	Description	Indications	Route of administration and dosage	
	CAPSULE OR TABLET	Depression.	Oral.	
	Each capsule or tablet contains:	Obsessive compulsive	Adults:	
	Sertraline hydrochloride equivalent to 50 mg. of sertraline.	disorders.	50 mg in the morning or at night.	
040.000.4484.00	Package with 14 capsules or tablets.		Maximum dose 200 mg/day.	

Generalities

Powerful and specific inhibitor of serotonin reuptake, an action that favors the serotonergic effect in the central nervous system.

Risk in Pregnancy b

Adverse effects

Nausea, diarrhea	, abdominal pain, dizziness, arterial hy	potension, palpitations, eder	na, male sexual dysfunction.
	Contraindi	cations and Precautions	٦
Contraindications	: Hypersensitivity to the drug, epilepsy		_
			lrug abuse. In the second half of pregnancy, illity, difficulty taking food and respiratory
,			-
		Interactions	<u></u>
	•		eins. Decreases the elimination of diazepan severe, life-threatening Serotonin Syndrome
SILDENAFIL			
Clue	Description TABLET	Indications Erectile dysfunction.	Route of administration and dosage Oral.
	TABLET	Erectile dysidriction.	Olai.
	Each tablet contains:		Adults:
	Sildenafil citrate equivalent to Sildenafil 100 mg.		50 to 100 mg, 30 to 60 minutes before sexual intercourse.
010.000.4309.00 010.000.4309.01	Package with 1 tablet. Package with 4 tablets.		
		Generalities	7
Selective inhibitor	r of cyclic guanosine monophosphate (J diesterase type 5 (PDE5).
	Risk in Pregnancy	d	
	The state of the s	Adverse effects	7
use of these med been reported ver		c neuropathy, which causes iduals have had the following	or priapism. An association between the permanent or transient vision loss, has grant characteristics: age over 50 years,
	Contraindi	cations and Precautions	Í
Contraindications Ischemic optic ne	: Hypersensitivity to the drug. Concom		c oxide, nitrate or organic nitrite donors.
should be analyze	ase of a history of sudden decrease or ed. In the event of a sudden decrease he medication and consult your doctor	in vision in one or both eyes,	eyes, the risk in the use of the medication

Enhances the hypotensive effects of nitrates used acutely or chronically.

SUCRALPHATE

Clue	Description	Indications	Route of administration and dosage
	TABLET	Duodenal ulcer.	Oral.
	Each tablet contains:	Gastric ulcer.	Adults:
	Sucralfate 1 g.		
		Gastritis.	1g four times a day or 2g twice a day.
010.000.5176.00	Package with 40 tablets.		

Generalities

It is a basic aluminum salt of sucrose octasulfate, it inhibits pepsin and absorbs bile salts, it acts on the ulcerated site by forming a protective barrier against the penetration and action of gastric acid.

Risk in Pregnancy b

Adverse effects

Dizziness, drowsiness, constipation, nausea, gastric upset, diarrhea.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: In kidney failure. Its safety and effectiveness in children have not been established.

None of clinical importance.

TAPENTADOL

Clue	Description	Indications	Route of administration and dosage
	RELEASE TABLET PROLONGED	Narcotic analgesic. Treatment of moderate to	Oral.
		severe chronic pain of	Adults:
	Each extended-release tablet contains:	oncological and non-	Titration: start treatment with doses of
		oncological origin,	50 mg every 12 hours, increasing by 50 mg every 3 days
	Tapentadol hydrochloride equivalent to 50 mg. of tapentadol.	requiring opioid analgesia.	until adequate pain control is achieved.
040.000.5915.00	Package with 30 prolonged release tablets.		Maintenance: Continue with the effective dose determined during titration every 12 hours.
	RELEASE TABLET		Maximum dose: 500 mg/day.
	PROLONGED		maximum coos. ooc mg cay.
	Each extended-release tablet contains:		
	Tapentadol hydrochloride equivalent to 100 mg. of tapentadol.		
040.000.5916.00	Package with 30 prolonged release tablets.		
	Ļ	I,	,I,

Tapentadol is a centrally acting synthetic analgesic that combines opioid and non-opioid activity in a single molecule. Their analgesic efficacy is related to their activity as opioid agonists of the ÿ receptor as well as the inhibition of norepinephrine reuptake.

Generalities

Risk in Pregnancy C

Adverse effects

Nausea, dizziness, constipation, drowsiness and headache.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug, significant respiratory depression; acute or severe bronchial asthma or hypercapnia; paralytic ileus; acute intoxication with alcohol, hypnotics, centrally acting analgesics or psychotropic drugs, MAO inhibitors; Severe liver or kidney insufficiency.

Cautions: Potential for abuse; respiratory depression; patients with brain damage and increased intracranial pressure; convulsions; patients with severe liver function impairment; patients with severe renal function impairment; pancreatic or bile duct disease.

0.9		
	Interactions	

Monoamine oxidase (MAO) inhibitors and patients who received other opioid receptor agonist analgesics, general anesthetics, phenothiazine, other tranquilizers, sedatives, hypnotics or other CNS depressants (including alcohol and illicit drugs) concomitantly may exhibit additive depression in the CNS.

BOTULINUM TOXIN TYPE A

Clue Description		Indications	Route of administration and dosage	
	INJECTABLE SOLUTION	Blepharospasm. Squint.	Intramuscular (in the affected muscle).	
	Each vial with powder contains:	Focal dystonias.	Blepharospasm, Strabismus, Focal dystonias, Palatine	
	On the studies was desiried A 400 LH	Palatine myoclonus.	myoclonus, Tremor,	
	Onabotulinum toxin A 100 U*	Tremor.	Spasmodic torticolitis	
	*Purified neurotoxin complex (900 KD) 100 U of onabotulinum toxin A contain	Spasmodic torticolitis	Adults:	
	4.8 ng of purified neurotoxin complex	Spasticity associated with stroke in adults.	Dosage according to the type and severity of the disease	
010.000.5666.00	Container with a vial.	Spasticity associated with infantile	Spasticity in adults and children over 2 years of age:	
		cerebral palsy.	Dosage according to the type and severity of the disease	

		Generalities	\neg
		ulinum and once injected, it bis	I nds to the presynaptic motor nerve terminal,
through selecti	ive receptors with high affinity towards	s serotype A.	
	Risk in Pregnancy	x	
		Adverse effects	\neg
Eyelid ptosis, p	pain, headache, dry eyes, subconjunc	tival hemorrhage, loss of visu	al acuity.
	Contrai	Indications and Precautions	\neg
Contraindication	ons: Hypersensitivity to the drug, infec	tion or inflammation at the site	e chosen for injection.
		Interactions	\neg
Its effect can be e	nhanced by the simultaneous use of aminoglyo	cosides and other medications that in	nterfere with neuromuscular transmission.
TRAMADO	L		
Clue	Description	Indications	Route of administration and dosage
	INJECTABLE SOLUTION	Moderate to pain severe of acute or chronic origin	Intramuscular or intravenous.
	Each vial contains: Tramadol	due to:	Adults and children over 14 years of age:
040.000.2106.00	Hydrochloride 100 mg.	Fractures.	50 to 100 mg every 8 hours.
040.000.2106.00	Container with 5 vials of 2 mL.	Dislocations. Acute myocardial	Maximum dose 400 mg/day.
		infarction. Cancer.	
	RELEASE TABLET PROLONGED	Pain treatment chronic of moderate to severe non-	Oral.
	Each extended-release tablet	oncological origin.	Adults:
	contains:		Titration: start with a dose of 150 mg once every 24 hours.
	Tramadol Hydrochloride 150 mg		If pain relief is not achieved, the dose should be
040.000.6140.00	Package with 10 prolonged release tablets.		adjusted slowly until relief is achieved.
040.000.6140.01	Package with 30 prolonged release tablets.		Mariana and the same of the sa
			Maintenance: continue with the effective dose determined during titration every 24 hours.
			The total daily dose of 400 mg should not be exceeded except for use in special clinical
l			circumstances.
		Generalities	
			onist of the mu, delta, kappa opioid receptor
•	iffinity to the mu receptor. Another me ake of norepinephrine and 5HT.	cnanism that may contribute t	o its analgesic effect is the inhibition of
·	Diele in Dramana.	C	
	Risk in Pregnancy		
B		Adverse effects	
	isea, vomiting, dry mouth, headache, lety, nervousness, gastrointestinal disc		dycardia, dyspnea, anorexia, diarrhea,
		ndications and Precautions	
			with alcohol, hypnotics, analgesics that act itors or who have received them within the
	Patients with epilepsy who are not ade		
		Interactions	
Concomitant a depressant effort		entrally acting medications, in	cluding alcohol, may potentiate the CNS
TRAMADO	L-PARACETAMOL		
Clue	Description	Indications	Route of administration and dosage

	TABLET	Moderate to severe pain,	Oral
		acute or chronic.	
	Each tablet contains:		Adults and people over 16 years of age:
	Tramadol Hydrochloride 37.5 mg.		
	Paracetamol 325.0 mg.		37.5 mg/325 mg to 75 mg/650 mg every 6 to 8 hours,
			to a maximum of 300 mg/
040.000.2096.00	Package with 20 tablets.		2600 mg per day.

Generalities

Tramadol is a centrally acting analgesic. It has two mechanisms of action, binding of an M1 metabolite to receptors ÿ-opioids and weak inhibition of norepinephrine and serotonin reuptake.

Paracetamol is another centrally acting analgesic. Its mechanism of action is through inhibition of the nitric oxide channel and mediated by the wide variety of neurotransmitter receptors that include N-methyl-D aspartate and substance P.

Risk in Pregnan	, x	
42	Adverse effects	
droweinoec		

Vertigo, nausea and drowsiness.

Contraindications and Precautions

Contraindications: Hypersensitivity to drugs, alcohol, hypnotics, analgesics with central action, opioids or psychotropic drugs.

Precautions: It should not be coadministered in patients receiving MAO inhibitors or who have taken them within the previous 14 days.

Interactions

MAO and serotonin reuptake inhibitors, Carbamazepine, Quidine, Warfarin and CYP2D6 inhibitors.

VENLAFAXINE

Clue	Description	Indications	Route of administration and dosage
	CAPSULE OR DRAGEEE	Depression.	Oral.
	EXTENDED RELEASE	·	
			Adults:
	Each extended-release capsule or lozenge		
	contains:		75-225 mg every 24 hours.
	Venlafaxine hydrochloride		
	equivalent to 75 mg of venlafaxine.		
010.000.4488.00	,		
	Package with 10 extended-release capsules		
	or dragees.		

Generalities

It is an antidepressant whose release is controlled by diffusion through the cell membrane and is not pH dependent. It is a potent inhibitor of neuronal serotonin and norepinephrine reuptake.

Risk in Pregnancy c

Adverse effects

Asthenia, fatigue, high blood pressure, vasodilation, decreased appetite, nausea, vomiting.

Contraindications and Precautions

Contraindications: Hypersensitivity to the drug.

Precautions: Frequent measurements of blood pressure and intraocular pressure, especially in high blood pressure and glaucoma. In the second half of pregnancy, the risk of Persistent Pulmonary Hypertension of the Newborn (PN) increases; irritability, difficulty taking food and respiratory difficulty in RNs.

Interactions

With monoamine oxidase inhibitors, indinavir, warfarin, ethanol and haloperidol. With triptans (eletriptan, rizatriptan, sumatriptan and zolmitriptan) severe, life-threatening Serotonin Syndrome occurs.